Document:

Exhibit 10.71

 

INVESTMENT RIGHTS AGREEMENT

 

This Investment Rights Agreement (“Agreement”) entered into on this 21st day of December 2009, by and among:

 

A.                                    IL&FS TRUST COMPANY LIMITED, a company incorporated under the Companies Act, 1956 having its Registered Office at The IL&FS Financial Centre, Plot No C-22, G Block, Bandra Kuria Complex, Bandra (East), Mumbai 400 051, as the trustee (“Trustee”) of the IL&FS Private Equity Trust, a trust established under the Indian Trusts Act, 1882, which is a Venture Capital Fund registered with the Securities and Exchange of India, investing through its venture capital scheme Leverage India Fund, which shall, unless repugnant to the subject or context, mean and include the Trustee for the time being and from time to time of the said trust, its successors and assigns acting through its investment manager IL&FS INVESTMENT MANAGERS LIMITED, a company incorporated in India under the Companies Act, 1956 and having its registered office at the IL&FS Financial Centre, C-22, G Block, Bandra Kuria Complex, Bandra (East), Mumbai - 400 051, India (hereinafter referred to as “Investor”, which expression shall, unless repugnant to the context or meaning thereof, mean and include its successors and assigns);

 

B.                                    NAPO PHARMACEUTICALS INDIA PRIVATE LIMITED, a company organised and existing under the Companies Act, 1956, whose registered office is at Office No. 1Z, 91, Nagdevi X Lane, 2nd Floor Mumbai 400080, India, (hereinafter referred to as “NPIP” which expression shall, unless repugnant to the context or meaning thereof, be deemed to include its successors and permitted assigns);

 

C.                                    NAPO PHARMACEUTICALS, INC., a company organised and existing under laws of the State of Delaware, USA, whose registered office is at 250 E.  Grand Avenue., Suite 70, South San Francisco, California 94080, USA (hereinafter referred to as “Napo” which expression shall, unless repugnant to the context or meaning thereof, be deemed to include its successors and permitted assigns).

 

Napo and NPIP, and the Investor are hereinafter individually referred to as “Party” and collectively as “Parties”.

 

WHEREAS:

 

A.                                    NPIP is engaged in the business of conducting research and development activities for certain pharmaceuticals (“Business”).

 

B.                                    The Parties had entered into a investment rights agreement dated December 9, 2008 (“Previous Agreement”) to govern the relationship between Napo, NPIP and the Investor.  The Parties propose to terminate the Previous Agreement, which shall be superceded by this Agreement.

 

C.                                    NPIP and Napo have approached the Investor with their proposal of investment in NPIP and the Investor has accepted such proposal by agreeing to invest in NPIP the INR equivalent of INR 19,999,900/- (“Investment Amount”) and the Shares Investment

 

 

Amount in NPIP (Investment Amount and Shares Investment Amount are collectively referred to as Total Investment Amount).  The Shares Investment Amount (as defined in the Subscription Agreement) is to be invested by subscription to 10 Shares (“Initial Shares”) and the Investment Amount is to be invested by subscription to 400,000 OCRPSs (as defined in the Subscription Agreement) (the Shares including the Converted Shares and the OCRPSs are hereinafter collectively referred to as “NPIP Equity”) to be issued by NPIP to the Investor.

 

D.                                    Within five (5) Business Days after the Investor has invested the Total Investment Amount in NPIP, and has subscribed to the NPIP Equity, NPIP shall invest an amount equal to the Investment Amount in Napo.  NPIP shall make such investment by subscription to the NPIP Napo Common Stock (as defined hereinafter) to be issued to NPIP by Napo at a price per Common Share as set out in the Subscription Agreement.

 

E.                                     Pursuant to the subscription agreement as of the date hereof entered into among Napo, NPIP, and the Investor (the “Subscription Agreement” and, together with this Agreement, the “Transaction Agreements”), the Investor has subscribed to the NPIP Equity.

 

F.                                      The Parties are entering into this Agreement for the purpose of recording the terms and conditions regulating the relationship of the Investor, Napo, and NPIP for certain matters including relating to the transfer of the NPIP Equity, and the management and operation of NPIP and their mutual rights and obligations.

 

1)                                     DEFINITIONS AND INTERPRETATION

 

a)                                     In this Agreement, unless the context requires otherwise, capitalised terms have the meaning ascribed to them in this Clause 1.  Capitalised terms not otherwise defined herein shall have the meaning ascribed to them in the Subscription Agreement:

 

“Affiliate” means and includes any entity that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a Party, where control means the ownership or control, directly or indirectly, of more than fifty percent of all of the voting power of the shares (or other securities or rights) entitled to vote for the election of directors, managers or other governing authority.  In relation to the Investor, the term Affiliate shall also mean and include any fund under the management of the Investor and/or under the management/ advice of the investment manager of the Investor and/or under the management/ advice of the Subsidiary of the investment manager of the Investor and/or under the management/advice of any joint venture company in which the investment manager of the Investor holds twenty six per cent (26%) or more of the shares on a fully diluted basis.

 

“Business Day” means any day other than a Saturday, a Sunday or any day on which banks in New York City (United States of America) and Mumbai (India) are permitted to be closed.

 

“Corporate Reorganization” means the sale of all or substantially all of the assets of Napo authorized by Napo and/or its stockholders in accordance with applicable Law, or a

 

 

merger or consolidation of Napo into or with another corporation for cash and/or other consideration.

 

“Corporate Reorganization Consideration” means the consideration received by Napo’s stockholders for their stock in Napo in connection with a Corporate Reorganization (net of any charges related to the receipt of such consideration, including but not limited to commissions and taxes of any kind and taxes that may be owed by NPIP to any Governmental Authority in respect of such consideration).

 

“Effective Date” means the Completion Date, as defined in the Subscription Agreement.

 

“Encumbrance” means any mortgage, charge (whether fixed or floating), pledge, lien, hypothecation, assignment, deed of trust, security interest, option, voting arrangement or other encumbrance of any kind.

 

“Exempted New Securities” means Securities issued pursuant to or in connection with: (i) sale/offerings pursuant to a registration statement filed under the Securities Act, 1933, or under any comparable securities law(s) for any recognized stock exchange, or Securities issued pursuant to or in connection with a listing under (a) the Alternative Investment Market operated by the London Stock Exchange (“AIM”) or (b) the London Stock Exchange; (ii) a merger or acquisition of another Person with the Napo Group or any other issuance of securities (and any issuance of securities upon conversion thereof) pursuant to the acquisition of another Person by the Napo Group by consolidation, merger, purchase of assets, or any other reorganization or transaction in which the Napo Group acquires any of the assets of such person or any voting power of such person; (iii) stock splits, stock dividend or recapitalization or distribution of profits as approved by the board of directors of NPIP or Napo; (iv) strategic acquisitions or transactions, including but not limited to joint ventures/partnerships/alliances with vendors or those pursuant to marketing/distribution or licensing arrangements; (v) exercise or conversion of outstanding convertible securities and any securities issuable upon the conversion thereof; (vi) any incentive equity or compensation plan of NPIP or Napo, including but not limited to stock options, stock or the exercise of stock options or other convertible securities issued to employees and/or directors; (vii) any incentive equity or compensation plan of Napo, including but not limited to stock options, stock or the exercise of stock options or other convertible securities issued to Persons who add value to the main business of Napo as determined in the sole and absolute discretion of Napo’s Board of Directors other than to employees and Directors of Napo; provided, however, that the aggregate number of such aforesaid securities of Napo, issued after the Effective Date to aforesaid recipients other than employees and directors shall not exceed 2% of Napo’s fully diluted capital on an as converted/exercised basis as on the Effective Date and (viii) the licensing of or investments related to or based upon proceeds arising directly or indirectly from licensing Napo’s Crofelemer compounds by Napo.  For purposes of this definition, Person shall not include the Napo Group.

 

“Financial Year” means the financial year of Napo and NPIP, which ends on December 31 of the calendar year.

 

3

 

“Governmental Authority” means any nation or government or any province, state or any other political subdivision thereof, any entity, authority or body exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including any government authority, agency, department, board, commission or instrumentality of India or the United States of America or any political subdivision thereof or of any other applicable jurisdiction; any court, tribunal or arbitrator and any securities exchange or body or authority regulating such securities exchange.

 

“Investor Share Entitlement” means:

 

(a)                                 one (1) share of NPIP Napo Common Stock per OCRPS or one (1) share of NPIP Napo Common Stock per Converted Share held by the Investor, at the time of determination, as may be appropriately adjusted for applicable stock splits, bonus, combinations, reclassifications and the like, or

 

b)                                     in the event that the Investor exercises its rights under Clause 7(f) below, the larger of:

 

i)                                         one (1) Share per OCRPS, as may be appropriately adjusted for applicable stock splits, bonus, combinations, reclassifications and the like; or

 

ii)                                      such number of Shares, as provides the Investor with an IRR of 30% at the Follow on Investment Valuation.

 

“Law” means all applicable provisions of all (i) constitutions, treaties, statutes, laws (including the common law), codes, rules, regulations, ordinances or orders of any Governmental Authority, (ii) approvals of any Governmental Authority and (iii) orders, decisions, injunctions, judgments, awards and decrees of or agreements with any Governmental Authority.

 

“Liquidity Amount” means an amount, being the net proceeds received by NPIP from the sale of NPIP Napo Common Stock including any dividend or other compensation received by NPIP on the NPIP Napo Common Stock, (net of any charges related to the sale of the NP IP Napo Common Stock that would ordinarily apply to such sale of NPIP Napo Common Stock, including but not limited to commissions and taxes of any kind and taxes that may be owed by NPIP to any Governmental Authority as a result of such sale) or any other amount received by NPIP as a Napo Common Stock holder against NPIP Napo Common Stock(net of any charges related to the distribution on such NPIP Napo Common Stock that would ordinarily apply to such distribution, including but not limited to commissions and taxes of any kind and taxes that may be owed by NPIP to any Governmental Authority as a result of such distribution).

 

“Napo Common Stock” shall mean common stock of Napo.

 

“Napo Group” shall mean NPIP, or Napo, as the context may require or NPIP, and Napo, collectively.

 

4

 

“New Securities” means Securities other than the exercise or conversion of outstanding convertible securities and the issuance of stock options or stock or the exercise of stock options, issued pursuant to any incentive equity plan of NPIP.

 

“OCRPS” means an optionally convertible, redeemable, non-cumulative, non-participating preference share of NPIP having a par value of Rupee One (1), with a fixed dividend rate of 0.00001% which preference shares are: (i) convertible into Shares of NPIP; or (ii) exchangeable for NPIP Napo Common Stock (subject to compliance with applicable Law), or (iii) redeemable under certain circumstances, for an amount as set forth in this Agreement.

 

“Person” means any natural person, firm, company, Governmental Authority, joint venture, association, partnership or other entity (whether or not having separate legal personality).

 

“Pro Rata Share” means, with respect to any shareholder, the proportion that the number of Securities held by such Person bears to the aggregate number of Securities held by all Person, in each case on a fully diluted basis, in the respective company.

 

“Regulation S” means Regulation S, promulgated under the U.S.  Securities Act of 1933, as amended.

 

“Shares” means equity shares of NPIP having a par value of INR 10 with one vote per share including the Initial Shares

 

“Securities” means, with respect to any Person, such Person’s equity share capital, partnership interests or other ownership interests (including, without limitation, in the case of NPIP, Shares) or any options, warrants, loans or other securities that are directly or indirectly convertible into, or exercisable or exchangeable for, such equity share capital, partnership interests or other ownership interests.

 

“NPIP Napo Common Stock” means the Napo Common Stock issued to NPIP upon the purchase by NPIP of Napo Common Stock and shall include Securities resulting from stock splits, stock dividend or by recapitalization or distribution of profits or on a Corporate Reorganization.

 

“Subsidiary” or “Subsidiaries” means, with respect to any specified Corporate Entity, any other Corporate Entity directly controlled by such specified Corporate Entity.  For the purposes of this definition, “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”), as used with respect to any Corporate Entity, shall mean the beneficial ownership directly or indirectly of more than 50% of the voting securities of such entity or the possession of the power to direct or cause the direction of the management or policies of such Corporate Entity through the ownership of voting securities or any other means.  “Corporate Entity” shall mean a corporation, a partnership, a limited liability company, a trust, or any other entity or organization.

 

5

 

“Transfer” means to sell, gift, assign, amalgamate, merge or suffer to exist (whether by operation of law or otherwise) or create any Encumbrance on any Shares or any right, title or interest therein or otherwise to dispose of or alienate in any manner whatsoever.

 

c)                                      Interpretation:

 

i)                                         References to any Party shall, where the context permits, include such Party’s successors, legal representatives and permitted assigns;

 

ii)                                      The headings are inserted for convenience only and shall not affect the construction of this Agreement;

 

iii)                                   Unless the context requires otherwise, words importing the singular include the plural and vice versa, and pronouns importing a gender include each of the masculine, feminine and neuter genders; and

 

iv)                                  The words “hereof,” “hereunder” and “hereto,” and words of like import, refer to this Agreement as a whole and not to any particular Clause hereof.

 

2)                                     TERMINATION OF PREVIOUS AGREEMENT

 

a)                                     The Parties agree that, notwithstanding any provision in any of the Previous Agreement to the contrary, the Previous Agreement is hereby terminated effective as of the date of this Agreement.

 

b)                                     The Parties agree that, from the date of this Agreement, this Agreement and the Subscription Agreeement shall be the only agreement in relation to the rights and obligations of the Parties as regards regulating the relationship of the Investor, Napo, and NPIP for certain matters including relating to the transfer of the NPIP Equity, and the management and operation of NPIP and their mutual rights and obligations.

 

3)                                     TERMS OF THE OCRPSs

 

a)                                     Tenure of the OCRPSs.  Subject to the terms of this Agreement, the OCRPSs shall have a tenure of four (4) years from the Effective Date (“Tenure”).  Subject to the terms of this Agreement, the OCRPSs shall be compulsorily redeemable by NPIP upon the expiry of the Tenure.  The OCRPSs shall be exchanged, converted or redeemed in the manner and pursuant to the terms set forth in Clause 7.

 

4)                                     PURCHASE OF NPIP NAPO COMMON STOCK

 

a)                                     No later than five (5) Business Days after the issuance of the OCRPSs to the Investor, NPIP shall subscribe for, and Napo shall issue to NPIP, the NPIP Napo Common Stock in accordance with the terms of the Subscription Agreement.

 

b)                                     The NPIP Napo Common Stock issued by Napo shall be subject to the terms of the Transaction Agreements and shall contain a legend clearly specifying that the NPIP Napo Common Stock is subject to the terms of the Investment Rights Agreement dated

 

6

 

December 21, 2009 entered into between Napo, NPIP and Investor and no transfer of such shares will be made on the books of Napo unless accompanied by compliance with the terms of such Investment Rights Agreement.

 

c)                                      If the NPIP Napo Common Stock has not been issued by Napo to NPIP within seven (7) Business Days after the Investor has invested the Total Investment Amount in NPIP (or such later date as mutually agreed to between the Parties), then NPIP shall (and Napo undertakes that NPIP shall) redeem all the OCRPSs issued to the Investor on the eighth (8th) Business Day after the Investor has invested the Total Investment Amount in NPIP for an amount that is equal to 105% of the Investment Amount (without any deductions), and thereafter neither NPIP, Napo, or the Investor shall have any further rights or obligations under this Agreement.  Simultaneously, with the receipt of the aforesaid amount, the Investor shall sell and Napo shall have the right to purchase or nominate a Person to purchase the outstanding Initial Shares (such Initial Shares shall be transferred for a consideration being the par value of such Shares), such that when all the NPIP Napo Common Stock is redeemed, then the Investor shall have no further NPIP Equity or any other rights in NPIP, or under this Agreement.

 

5)                                     RIGHTS AND PREFERENCES OF THE INVESTOR

 

a)                                     Investor Transfer of Securities.  Subject to the conditions set forth herein below, the Investor or its Affiliates may Transfer all (and not part of) the OCRPSs (or the Converted Shares) along with all the other Shares held by it to any Person, subject to the requirements of applicable Laws, including specifically, applicable securities Laws of India and subject to such Person executing a Deed of Adherence as set forth in Annexure 1.  Such Transfer shall only be permitted so long as the transferee becomes a party to this Agreement, and shall have the rights and obligations of the Investor as set forth in this Agreement; provided, however, that the transferee shall not under any circumstances have any board rights or affirmative rights pursuant to Clause 9 below.  Notwithstanding the foregoing, subject to applicable Law, the Investor is free to Transfer their NPIP Equity to any of its Affiliates with all the rights of the Investor pursuant to this Agreement continuing to remain with the Investor.

 

b)                                     NPIP Transfer of Securities.  Except pursuant to Clauses 5(d)(i) and 7(e), so long as the Investor holds any NPIP Equity, NPIP shall not on its own accord Transfer the NPIP Napo Common Stock equivalent to the Investor Share Entitlement without the prior written consent of the Investor.

 

c)                                      Voting of NPIP Napo Common Stock.  If at any time there is a vote of stockholders of Napo, whether by written consent, or a stockholders meeting or in any other manner, NPIP shall exercise its vote(s) in the manner instructed by the Investor, the intent being that the Investor shall be entitled to vote those number of NPIP Napo Common Stock shares as equal to the Investor Share Entitlement.

 

d)                                     (i) Liquidation Preference.  If the Investor is holding NPIP Equity, then in the event of winding-up, dissolution and/or liquidation of Napo (except by virtue of a Corporate Reorganization as addressed in Clause 7(e) below), to the extent of funds legally

 

7

 

available, NPIP shall be permitted to sell the NPIP Napo Common Stock without the prior consent of the Investor, and the Investor shall be entitled to such an amount equal to the amount to which the Investor would be entitled as a creditor of NPIP up to the Liquidity Amount (net of any charges related to the receipt of such cash proceeds, including but not limited to taxes of any kind and taxes that may be owed by NPIP to any Governmental Authority as a result of such receipt).  In the event the amount available under applicable Law with NPIP to redeem the OCRPSs or in case of Converted Shares, to buy back the Converted Shares is less than the Liquidity Amount as a result of accumulated losses in NPIP or due to insufficient profits or funds for any other reason, Napo Group undertakes to immediately make available the necessary funds to NPIP to the extent of such differential amount in order to enable NPIP to redeem the applicable OCRPSs or in case of Converted Shares to buy back the Converted Shares for an amount equivalent to the Liquidity Amount.  Notwithstanding the foregoing or the following two sentences below, such obligation of Napo Group will not apply in any situation in which due to a change in applicable Law from the Effective Date or force majeure, the Napo Group are prohibited from delivering the Liquidity Amount in full to the Investor in connection with redeeming the OCRPSs or in case of Converted Shares to buy back the Converted Shares.  Until such redemption or buy back, Napo Group undertakes and is obligated not to use the Liquidity Amount for any other purpose.  Upon termination of such force majeure or a further change in applicable Law which no longer prohibits the Napo Group from delivering the Liquidity Amount in full to the Investor, the Napo Group shall redeem the OCRPSs or buy back the Converted Shares, as the case may be, and deliver the Liquidity Amount (or such portion as has not yet been delivered) to Investor.  If the Investor is holding NPIP Equity, then in the event of winding-up, dissolution and/or liquidation of Napo (except by virtue of a Corporate Reorganization as addressed in Clause 7(e) below), to the extent that proceeds of such winding-up, dissolution and/or liquidation are legally available for and distributed to Napo Common Stock holders, NPIP shall be entitled to its Pro Rata Share of such proceeds against NPIP Napo Common Stock and NPIP shall within fifteen (15) days of the receipt of the Liquidity Amount utilize the same to redeem the OCRPS or buy back the Converted Shares.

 

(ii) If the Investor is holding NPIP Equity, then in the event of winding-up, dissolution and/or liquidation of NPIP, NPIP shall be permitted to sell the NPIP Napo Common Stock with the prior consent of the Investor, and the Investor shall be entitled to such an amount equal to the amount to which the Investor would be entitled as a creditor of NPIP up to the Liquidity Amount (net of any charges related to the receipt of such cash proceeds, including but not limited to taxes of any kind and taxes that may be owed by NPIP to any Governmental Authority as a result of such receipt).  In the event the amount available under applicable Law with NPIP to redeem the OCRPSs or in case of Converted Shares, to buy back the Converted Shares is less than the Liquidity Amount as a result of accumulated losses in NPIP or due to insufficient profits or funds for any other reason, Napo Group undertakes to immediately make available the necessary funds to NPIP to the extent of such differential amount in order to enable NPIP to redeem the applicable OCRPSs or in case of Converted Shares to buy back the Converted Shares for an amount equivalent to the Liquidity Amount.  Notwithstanding the foregoing, such obligation of Napo Group will not apply in any situation in which due to a change in

 

8

 

applicable Law from the Effective Date or force majeure the Napo Group are prohibited from delivering the Liquidity Amount in full to the Investor in connection with redeeming the OCRPSs or in case of Converted Shares to buy back the Converted Shares.  Until such redemption or buy back, Napo Group undertakes and is obligated to not to use the Liquidity Amount for any other purpose.  Upon termination of such force majeure or a further change in applicable Law which no longer prohibits the Napo Group from delivering the Liquidity Amount in full to the Investor, the Napo Group shall redeem the OCRPSs or buy back the Converted Shares, as the case may be, and deliver the Liquidity Amount (or such portion as has not yet been delivered) to Investor.

 

e)                                      Pre-emptive Rights.  In the event that, after the Effective Date, and so long as the Investor holds any NPIP Equity, NPIP proposes to issue any New Securities (other than Exempted New Securities), the Investor shall have a preemptive right, to subscribe for a Pro Rata Share of such New Securities.  Not less than fifteen (15) Business Days before a proposed issuance of New Securities (a “Proposed Issuance”), NPIP shall deliver to the Investor a written notice of the Proposed Issuance setting forth (i) the number, type and terms of the Securities to be issued, (ii) the consideration to be received by NPIP in connection with the Proposed Issuance and (iii) the identity of the allottees.  Within ten (10) Business Days following delivery of the notice referred to in this Clause 5(e), the Investor, if it elects to exercise its rights under this Clause 5(e) shall give written notice to NPIP specifying the number of Securities to be purchased by the Investor (which shall not be greater than its Pro Rata Share of such New Securities) and NPIP shall issue and allot such number of New Securities to the Investor within five (5) Business Days thereafter, upon receipt of the consideration specified in the aforesaid notice.  Provided further that NPIP shall not issue any New Securities after the date of execution of this Agreement, as mentioned above, till the Completion Date, as defined in Subscription Agreement.

 

In the event that, after the Effective Date and until the Termination Date, and only so long as the Investor holds any NPIP Equity or NPIP Napo Common Stock as per Clause 7(a), Napo proposes to issue any New Securities (other than Exempted New Securities), the Investor shall have a preemptive right to subscribe for a Pro Rata Share of such New Securities on the terms and conditions offered by Napo (the “Pre-emptive Rights”).  Napo undertakes to issue to the Investor such New Securities as per its Pro Rata Shares of such New Securities if applicable Law allows the Investor to hold such New Securitis or to allow the Investor to subscribe to such New Securities by any of its Affiliates in accordance with the terms and conditions offered by Napo.  Prior to such issuance, Napo shall deliver a notice of the proposed issuance of New Securities to the Investor (a “Proposed Issuance”), Napo shall deliver to the Investor a written notice of the Proposed Issuance setting forth (i) the number, type and terms of the New Securities to be issued and (ii) the consideration to be received by Napo in connection with the Proposed Issuance (the “Preemptive Notice”).  Within ten (10) Business Days following delivery of the Preemptive Notice, the Investor, if it elects to exercise its rights under this Clause 5(e), shall give written notice to Napo specifying the number of New Securities to be purchased by the Investor or its Affiliates (which shall not be greater than its Pro Rata Share of such New Securities).  Napo shall issue and allot such number of New Securities as communicated by Investor to Napo within five (5) Business Days after receipt of the

 

9

 

consideration specified in the Preemptive Notice and Investor’s compliance with all other terms and conditions specified in the Preemptive Notice.  If the Investor fails to agree in writing within such ten (10) Business Day period to purchase Investor’s Pro Rata Share even after complying with all other terms in the Preemptive Notice within such ten (10) Business Days, it shall forfeit the right hereunder to purchase its Pro Rata Share of such New Securities.  “Termination Date” shall be the earlier of such time that Napo has (x) become a “reporting issuer” filing periodic reports (10-Qs/10-Ks/8-Ks) with the United States Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended, or (y) a merger or consolidation of Napo with or into another entity (other than a merger or consolidation with a wholly-owned subsidiary or a reincorporation of the Company in a different jurisdiction) or any Corporate Reorganization.  Napo shall have one hundred and twenty (120) Business Days following delivery of the Preemptive Notice to Investor to issue the New Securities not purchased by Investor.  Thereafter, Napo shall again comply with the Preemptive Rights provisions set forth in this paragraph until the Termination Date.  Notwithstanding the foregoing, if Investor is entitled to exercise Pre-emptive Rights under this paragraph and wishes to exercise the same by way of structure as availed under this Agreement because it is not eligible under applicable Law to acquire such New Securities directly, Napo undertakes to issue to the Investor such New Securities as per its Pro Rata Share of such New Securities by way of the structure as availed in this Agreement only if the Investor’s investment amount of its Pro Rata Share of such New Securities is at least equal to $500,000 and then Investor exercises its Pre-emptive Rights to invest no less than $500,000 in the issuance of such New Securities.

 

f)                                       Anti-Dilution Rights.  In the event that if, after the Effective Date but prior to redemption or exchange of the OCRPSs or buy back or exchange of the Converted Shares as the case may be in accordance with the terms of this Agreement, NPIP issues New Securities (other than Exempted New Securities) to any Person(s) other than to the Investor (“Follow on Investment Valuation”), in the event the Investor is holding OCRPS the number of Shares that the OCRPSs shall be converted into in the event that the Investor exercises its rights under Clause 7(f) below shall be adjusted, to reflect the price at which the New Securities are being offered, such that the number of Shares that the OCRPSs held by the Investor convert into (pursuant to Clause 7(f) below) is as per its Investor Share Entitlement and in the event the Investor is holding the Converted Shares, NPIP shall issue such additional Shares to the Investor to reflect the price at which the New Securities are being offered, such that the Investor holds such number of Shares, as provides the Investor with an IRR of 30% at the Follow on Investment Valuation.

 

g)                                      Dividends etc.  In the event that post the Effective Date and prior to redemption or exchange of the OCRPSs or buy back or exchange of the Converted Shares in accordance with the terms of this Agreement, Napo declares and pays a dividend, bonus or other entitlement on the NPIP Napo Common Stock, the Investor will be entitled to any such dividend, bonus and other entitlements on the NPIP Napo Common Stock, in proportion to its Investor Share Entitlement (net of any charges related to such dividends, bonuses and other entitlements that would ordinarily apply to such payments including but not to taxes of any kind and taxes that may be owed by NPIP to any Governmental Authority as a result of the receipt of such payment) in accordance with the terms of this Agreement.

 

10

 

6)                                     UNDERTAKINGS AND REPRESENTATIONS BY NAPO

 

a)                                     Napo hereby undertake as follows:

 

i)                                         Non-Transfer of NPIP Shareholding.  Except pursuant to or until a Corporate Reorganization occurring after NPIP acquires the NPIP Napo Common Stock, neither Napo (or its successors in interest), shall directly or indirectly Transfer its shareholding, or any portion of such shareholding, in NPIP until the earlier of the following: (i) termination of this Agreement; or (ii) the Investor having exchanged the OCRPSs or Converted Shares for NPIP Napo Common Stock or redeemed its OCRPSs and transferred its Shares; or (iii) the consent of the Investor has been obtained for such Transfer.  However, in the event of a Corporate Reorganization, Napo Group undertakes that Napo Group and/or the new entity resulting from the Corporate Reorganization will guarantee the performance of the Transaction Agreements in all respects as per the existing obligations of Napo Group under the Transaction Agreements until the Investor receives the Liquidity Amount or the Corporate Reorganization Consideration as per Clause 7(e) of this Agreement, as may be applicable.

 

ii)                                      Prohibition on Encumbrance.  Except pursuant to or until a Corporate Reorganization occurring after NPIP acquires the NPIP Napo Common Stock, Napo shall not create an Encumbrance over its shareholding or any portion of its shareholding in NPIP until the earlier of the following: (i) termination of this Agreement; or (ii) the Investor has exchanged the OCRPSs or Converted Shares for NPIP Napo Common Stock or redeemed its OCRPSs and transferred its Shares; or (iii) the consent of the Investor has been obtained for such Transfer.  However, in the event of a Corporate Reorganization, Napo Group undertakes that Napo Group and/or the new entity resulting from the Corporate Reorganization will guarantee the performance of the Transaction Agreements in all respects as per the existing obligations of Napo Group under the Transaction Agreements until the Investor receives the Liquidity Amount or the Corporate Reorganization Consideration as per Clause 7(e) of this Agreement, as may be applicable.

 

iii)                                   Amendment to Charter Documents.  NPIP shall, on or before Completion Date, amend the relevant provisions of the articles of association and bylaws of NPIP to incorporate therein the provisions of this Agreement and the Subscription Agreement.  The revised articles of association of NPIP shall be in a form satisfactory to the Investor.

 

7)                                     EXCHANGE, CONVERSION OR REDEMPTION OF OCRPSs OR BUY BACK OF CONVERTED SHARES

 

a)                                     If, prior to the expiry of the Tenure of the OCRPS held by the Investor or buy back of the the Converted Shares by NPIP held by the Investor, the Investor wishes to exchange the OCRPSs or Converted Shares, as the case may be, for NPIP Napo Common Stock, then subject to and in accordance with applicable Law, within thirty (30) Business Days

 

11

 

thereof, Napo Group undertakes to exchange the NPIP Napo Common Stock for all the OCRPSs then held by the Investor or the Converted Shares then held by the Investor for the Investor’s Share Entitlement (“Exchange Right”).  Such exchange shall be done as per applicable Law without any additional cost to be incurred by Investor; provided, however, that the Napo Group shall not incur more than INR 250,000.  Provided that, simultaneously with such exchange, the Investor shall Transfer all the NPIP Equity held by it to NPIP or Napo, or such other Person as nominated by Napo, as per applicable Law, and in the case of the Initial Shares, such Initial Shares shall be transferred for a consideration being the par value of such Shares.  It is hereby clarified that, upon exercise of the Exchange Right, and upon consequent transfer of the Investor Share Entitlement to the Investor, the Investor shall only have the rights as stockholders that all other holders of Napo Common Stock would have.

 

b)                                     INTENTIONALLY LEFT BLANK

 

c)                                      At anytime, subject to and in compliance with applicable Law, the Investor shall have the right to cause NPIP to sell in part or full up to such number of NPIP Napo Common Stock shares as equal to such Investor’s Share Entitlement as directed by the Investor at the price determined by the Investor; provided, however, that NPIP has no obligation to sell such NPIP Napo Common Stock if there is no willing buyer for such NPIP Napo Common Stock at the price requested by the Investor (and shall have no additional obligations to pay any transfer fees or expenses except to advance any customary brokerage fees, if any, which will be calculated in determining the Liquidity Amount or any other net proceeds in any event).  Upon sale of the NPIP Napo Common Stock, NPIP shall utilize the Liquidity Amount subject to the provisions of the Companies Act, 1956, and prior to use of such proceeds for any other purpose, to redeem such number of OCRPSs held by the Investor as determined below in this clause or to buy back such number of Converted Shares held by the Investor as determined below in this clause; provided, however, that the Investor’s right to instruct NPIP to transfer the NPIP Napo Common Stock, and NPIP’s obligation to transfer the NPIP Napo Common Stock, shall also be subject to any applicable Laws and regulatory holding periods.  In the event the amount available under applicable Law with NPIP to redeem the OCRPSs or to buy back the Converted Shares held by the Investor is less than the Liquidity Amount as a result of accumulated losses in NPIP or due to insufficient profits or funds for any other reason, Napo Group undertakes to immediately make available the necessary funds to NPIP to the extent of such differential amount in order to enable NPIP to redeem the applicable OCRPS’s or to buy back the Converted Shares held by the Investor for an amount equivalent to the Liquidity Amount.  Notwithstanding the foregoing, such obligation of Napo Group will not apply in any situation in which due to a change in applicable Law from the Effective Date or force majeure, the Napo Group are prohibited from delivering the Liquidity Amount in full to the Investor in connection with redeeming the OCRPSs or to buy back the Converted Shares held by the Investor.  However, until such redemption or buy back, Napo Group undertakes and is obligated to not to utilize the Liquidity Amount for any other purpose.  Upon termination of such force majeure or a further change in applicable Law which no longer prohibits the Napo Group from delivering the Liquidity Amount in full to the Investor, the Napo Group shall redeem the OCRPSs or buy back the Converted Shares, as the case may be, and deliver the Liquidity Amount (or

 

12

 

such portion as has not yet been delivered) to Investor.  Subject to the foregoing, within fifteen (15) Business Days from the receipt of the Liquidity Amount, NPIP shall utilize the Liquidity Amount, subject to the provisions of the Companies Act, 1956, and applicable Law, to redeem such number of OCRPSs or to buy back such number of Converted Shares held by the Investor in the ratio of the Investor Share Entitlement with respect to the number of shares of NPIP Napo Common Stock sold (adjusted appropriately for stock splits, combinations, reclassifications and the like).  Simultaneously, with the receipt of the Liquidity Amount, the Investor shall sell and Napo shall purchase or nominate a Person to purchase such number of the Initial Shares, pro rated with respect to the number of shares of NPIP Napo Common Stock sold (such Initial Shares shall be transferred for a consideration being the par value of such shares).  This pro rated sale of the Initial Shares shall apply to each successive sale of NPIP Napo Common Stock, such that when all the NPIP Napo Common Stock (but in no event required to be in excess of Investor’s Share Entitlement) is finally sold, then the Investor shall have no further NPIP Equity or any other rights in NPIP, or under this Agreement.

 

d)                                     If the Investor has not fully exercised its rights pursuant to Clause 7(c) above, then immediately upon expiry of the Tenure, NPIP shall, with the prior consent of the Investor, have the right to sell the outstanding NPIP Napo Common Stock held by NPIP and use the proceeds obtained therefrom to compulsorily redeem the outstanding OCRPS and credit to the Investor’s account an amount equivalent to the Liquidity Amount applicable to such outstanding OCRPS within fifteen (15) days of the date of expiry of the Tenure.  In the event the amount available under applicable Law with NPIP to redeem the OCRPSs is less than the Liquidity Amount applicable to such outstanding OCRPSs as a result of accumulated losses in NPIP or due to insufficient profits or funds for any other reason, Napo Group undertakes to immediately make available the necessary funds to NPIP to the extent of such differential amount in order to enable NPIP to redeem the applicable OCRPS’s for an amount equivalent to the Liquidity Amount.  Simultaneously, with the receipt of the Liquidity Amount, the Investor shall sell and Napo shall purchase or nominate a Person to purchase the outstanding Initial Shares (such Initial Shares shall be transferred for a consideration being the par value of such shares), such that when all the NPIP Napo Common Stock is finally sold, then the Investor shall have no further NPIP Equity or any other rights in NPIP, or under this Agreement.

 

e)                                      Notwithstanding the foregoing, in the event of a Corporate Reorganization where the Investor has not fully exercised its rights pursuant to Clause 7(c) above, then upon consummation of the Corporate Reorganization, NPIP shall redeem the OCRPS then outstanding and credited to the Investor’s account(s) in consideration of the Corporate Reorganization Consideration attributable to the NPIP Napo Common Stock and thereafter allocated to the Investor based on the Investor’s Share Entitlement, and in case the Investor is holding Converted Shares pursuant to Clause 7(f) below, NPIP shall buy back the Converted Shares held by the Investor and credited to the Investor’s account(s) in consideration of the Corporate Reorganization Consideration attributable to the NPIP Napo Common Stock and thereafter allocated to the Investor based on the Investor’s Share Entitlement, which consideration if in cash shall be credited to a bank account as designated by the Investor and otherwise appropriately transferred to the Investor; provided, however, that if the Corporate Reorganization Consideration is equity and the

 

13

 

Investor is not eligible under applicable Law to receive equity securities as the Corporate Reorganization Consideration, at the option of the Investor, either (X) NPIP shall establish a structure reasonably acceptable to the Investor that would permit the Investor to retain the beneficial interest in such Corporate Reorganization securities pari passu with the Investor’s beneficial interest through the OCRPSs or Converted Shares in the NPIP Napo Common Stock or (Y) if the third-party acquiror is a privately held corporation, the Investor may elect to receive cash in lieu of establishing such a structure, and Napo shall in good faith but with no legal or contractual obligation attempt to pay and NPIP shall pay the Investor the fair market value of such securities in cash as such equity securities are valued in the Corporate Reorganization (net of any charges related to the receipt of such consideration, including but not limited to commissions and taxes of any kind and taxes that may be owed by NPIP to any Governmental Authority in respect of such consideration).  In the event the amount available under applicable Law with NPIP to redeem the OCRPSs or buy back the Converted Shares held by the Investor is less than the Corporate Reorganization Consideration attributable to the NPIP Napo Common Stock and thereafter allocated to the Investor based on Investor’s Share Entitlement applicable to such outstanding OCRPSs or Converted Shares as a result of accumulated losses in NPIP or due to insufficient profits or funds for any other reason, Napo Group undertakes to immediately make available the necessary funds to NPIP to the extent of such differential amount in order to enable NPIP to redeem the applicable OCRPS’s or buy back the Converted Shares for an amount equivalent to the Corporate Reorganization Consideration attributable to the NPIP Napo Common Stock and thereafter allocated to the Investor based on Investor’s Share Entitlement.  Simultaneously, with the aforesaid, the Investor shall sell and Napo shall purchase or nominate a Person to purchase the outstanding Initial Shares (such Initial Shares shall be transferred for a consideration being the par value of such shares), such that when all the NP IP Napo Common Stock (but in no event required to be in excess of Investor’s Share Entitlement) is finally sold, then the Investor shall have no further NPIP Equity or any other rights in NPIP, or under this Agreement.

 

f)                                       At any time during the Tenure, the Investor shall be entitled to convert the OCRPSs then outstanding and NPIP shall issue to the Investor such number of Shares being equivalent to the Investor Share Entitlement (“Converted Shares”); provided, however, that the Investor shall exercise the conversion option attached to all the OCRPSs held by it in a single instance and such conversion is subject to and in compliance with all applicable Laws.

 

Napo Group hereby undertakes that in the event the Investor has exercised its option under this Clause 7(f), in all the scenarios of distribution of Liquidity Amount Napo shall not offer its Shares to NPIP in the process of buy back of Converted Shares by NPIP.

 

g)                                      Notwithstanding anything to the contrary mentioned in this Agreement, in the event the Investor ceases to hold all the OCRPSs (and consequently any Shares including Converted Shares) whether by exchange, or redemption, or buy back and has received all amounts owed to it pursuant to this Agreement, the Investor will cease to have any rights or interest in relation to the OCRPSs or Converted Shares, or any rights or interest in the

 

14

 

NPIP Napo Common Stock, Napo, or NPIP and this Agreement shall terminate with respect to the Investor in accordance with Clause 17 hereto.

 

8)                                     EXIT MECHANISM

 

a)                                     Liquidity Events.  The Napo Group agree to work towards creating a Liquidity Event, such as one listed in Clause 8(b) below, for the investment of the Investor pursuant to this Agreement within a period of three years from the Effective Date.  Napo Group shall bear all expenses for the Liquidity Event.

 

b)                                     Possible Liquidity Events.  The Parties shall in good faith consider any one of the following actions as a Liquidity Event:

 

i)                                         Listing of shares of NPIP through an IPO or Offer for Sale;

 

ii)                                      Sale of NPIP’s entire business or 100% of its share capital including OCRPS;

 

iii)                                   Buyback of Securities;

 

iv)                                  Merger of NPIP with other listed companies.

 

9)                                     ACCOUNTS AND CORPORATE GOVERNANCE (INFO RIGHTS)

 

a)                                     Auditors.  Napo Group shall appoint reputable auditors to audit the accounts and financial statements of Napo, NPIP and their respective Subsidiaries.

 

b)                                     Board and Investor Director.  The Board of NPIP shall consist of at least three (3) directors and up to five (5) Directors.  So long as the Investor holds any OCRPSs or Shares purchased hereunder or Converted Shares, it shall have the right to appoint a Director to the Board of NPIP (the “Investor Director”) until the termination of this Agreement in accordance with its terms.

 

c)                                      Rights of Investor Director.  The Investor Director shall have the same voting rights as any other director on the board of directors and committees of NPIP, subject to applicable Law and this Agreement.  The Investor Director shall be given notice of all meetings in accordance with the bylaws.

 

d)                                     Reasonable Expenses.  All reasonable and documented expenses incurred by the Investor Director for attendance at a meeting of the board of directors or committees of NPIP shall be borne by NPIP.

 

e)                                      Notice.  A meeting of the board of directors of NPIP may be called in accordance with the bylaws or articles of association.  The Investor Director shall be entitled to a written agenda, which may be delivered by electronic mail or otherwise, specifying in reasonable detail the business of such meeting.  Subject to the above, NPIP (as the case may be) shall ensure that notice of a meeting of the board of directors is received in compliance with applicable Law and the bylaws or articles of association at least five (5) Business Days prior to such meeting of the board of directors.

 

15

 

f)                                       Telephonic and Video-Conferencing Participation.  If permitted by applicable Law and the articles of association of NPIP, the Investor Director may at his or her option participate in meetings of the board of directors by telephone or video conferencing or any other means of contemporaneous communication, provided that the Investor Director must acknowledge his presence for the purpose of the meeting and the Investor Director not doing so shall not be entitled to speak or vote at the meeting.  The Investor Director may not leave the meeting by disconnecting his telephone or other means of communication unless he has previously obtained the express consent of the chairman of the meeting and the Investor Director shall conclusively be presumed to have been present and formed part of the quorum at all times during the meeting unless he has previously obtained the express consent of the chairman of the meeting to leave the meeting as aforesaid.

 

g)                                      Affirmative Voting Matters.  Until the termination of this Agreement in accordance with Clause 17, no action set forth below may be taken by NPIP at a meeting of the board of directors (or committee thereof) or by circular resolution or at a shareholders’ meeting, in connection with any of the matters set forth in this Clause 9(g) without the affirmative vote of the Investor Director (in the case of a meeting of the board of directors (or committee thereof) or by circular resolution) and the Investor in the case of shareholders meeting, without which such matter shall be deemed not to be approved by the Board, committee or shareholders.  The Investor agrees not to unreasonably withhold, condition or delay its affirmative vote in respect of such matters.  The matters which shall be subject to the provisions of this Clause 9(g) are:

 

i)                                         So long as the Investor holds any OCRPSs or Converted Shares, any action that authorizes, creates or issues debt instruments superior to the terms of the NPIP Equity including but not limited to payment preferences over the OCRPSs or Converted Shares.

 

ii)                                      Any amendments to the memorandum of association, articles of association or by-laws of NPIP to the extent such amendment adversely affects the rights and interest of the Investors.  Notwithstanding the foregoing, the provisions of this Agreement shall not be modified without the written consent of the Investors.

 

iii)                                   Any changes in the accounting year of NPIP.

 

iv)                                  Undertaking any business other than the Business.

 

v)                                     Issuance of New Securities by NPIP, buy-back, re-purchase, redemption of Securities of NPIP, reduction of the share capital of NPIP or any other change in capital structure of NPIP.

 

vi)                                  Utilisation of the Securities Premium Account of NPIP for any purpose

 

vii)                               Any liquidation, winding up, dissolution, disposition, sale or transfer of all or substantially all of the assets of NPIP or a merger or consolidation of NPIP into or with another corporation for cash and/or other consideration, except pursuant to a Corporate Reorganization.

 

16

 

viii)                            Change in the size of the Board of NPIP such that the number of Directors is reduced below 3 or increased to more than 5.

 

h)                                     Budgetary and Financial Estimates.  Prior to the commencement of any Financial Year, until the termination of this Agreement, the board of directors of NPIP shall approve on an annual basis the following:

 

i)                                         Estimated sources and applications of funds;

 

ii)                                      Estimated profit and loss account;

 

iii)                                   Estimated balance sheet; and

 

iv)                                  Detailed assumptions underlying the forecasts for sub-clauses (i) — (iii); above.

 

i)                                         Use of Funds.  NPIP shall utilize the Investment Amount exclusively for the purposes of subscribing to the NPIP Napo Common Stock in accordance with the Transaction Agreements.

 

10)                              DEFAULT AND REMEDY

 

a)                                     In the event of any Party committing a breach of any of its material obligations pursuant to and in accordance with this Agreement and the Subscription Agreement and failing to rectify the same within a period of fifteen (15) Business Days of receipt of a written notice of such breach, the aggrieved Party shall be entitled to invoke the dispute resolution provision set forth in Clause 16(b) below, and may exercise all its rights in law, equity or otherwise including termination of this Agreement.

 

11)                              REPRESENTATIONS AND WARRANTIES

 

a)                                     Each Party represents, severally and not jointly, to the other Parties hereto that:

 

i)                                         such Party has the full power and authority to enter into, execute and deliver this Agreement including under its charter documents and to perform the transactions contemplated hereby and, if such Party is not a natural Person, such Party is duly incorporated or organised with limited liability and existing under the laws of the jurisdiction of its incorporation or organisation;

 

ii)                                      the execution and delivery by such Party of this Agreement and the performance by such Party of the transactions contemplated hereby have been duly authorised by all necessary corporate or other action of such Party;

 

iii)                                   assuming the due authorisation, execution and delivery hereof by the other Parties, this Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally; and

 

17

 

iv)                                  the execution, delivery and performance of this Agreement by such Party and the consummation of the transactions contemplated hereby will not (i) violate any provision of the organisational or governance documents of such Party, (ii) require such Party to obtain any consent, approval or action of, or make any filing with or give any notice to, any governmental authority in such Party’s country of organisation or any other Person pursuant to any instrument, contract or other agreement to which such Party is a party or by which such Party is bound, other than as specifically contemplated or set forth in this Agreement and the Subscription Agreement; (iii) conflict with or result in any material breach or violation of any of the terms and conditions of, or constitute (or with notice or lapse of time or both constitute) a default under, any instrument, contract or other agreement to which such Party is a party or by which such Party is bound, (iv) violate any order, judgment or decree against, or binding upon, such Party or upon its respective securities, properties or businesses, or (v) other than as contemplated or set forth in this Agreement violate any Law or regulation of such Party’s country of organisation or any other country in which it maintains its principal office.  Without limiting the exceptions to the foregoing, it is acknowledged and contemplated that applicable securities laws and employment laws and public policy may limit the actions or require prior consents to the performance of the Napo Group’s or the Investor’s obligations hereunder.

 

b)                                     The Napo Group represents and warrants that the transactions contemplated herein are in accordance with Law and that no regulatory approvals are required by it to enter into this and to perform its obligations hereunder.

 

12)                              CONFIDENTIALITY

 

a)                                     The Investor undertakes that it shall not reveal, and shall use its reasonable efforts to ensure that its directors, officers, managers, partners, members, employees, legal, financial and professional advisors and bankers (collectively, “Representatives”) do not reveal, to any third party any Confidential Information without the prior written consent of Napo.  The term “Confidential Information” as used in this Agreement means (a) any information concerning the organisation, business, technology, trade secrets, know-how, finances, transactions or affairs of NPIP or Napo or any other Party or any of their respective Representatives or affiliates (whether conveyed in written, oral or in any other form and whether such information is furnished before, on or after the date hereof), (b) any information or materials prepared by a Party or its Representatives that contains or otherwise reflects, or is generated from, Confidential Information and (c) the terms of this transaction (except to the extent and in the manner as the transaction is required under applicable Law to be disclosed or may be publicly announced or published by mutual written agreement among the parties.)

 

b)                                     Napo, and NPIP undertake that they shall not reveal, and shall use their respective reasonable efforts to ensure that their respective Representatives do not reveal, to any third party any Confidential Information of any Investor without the prior written consent of such Investor.

 

18

 

c)                                      Notwithstanding the foregoing, the provisions of Clause 12(a) and Clause 12(b) shall not apply to:

 

i)                                         disclosure of Confidential Information that is or becomes generally available to the public other than as a result of disclosure by or at the direction of a Party or any of its Representatives in violation of this Agreement;

 

ii)                                      disclosure by a Party to its Representatives provided such Representatives are bound by similar confidentiality obligations;

 

iii)                                   disclosure, after giving prior notice to the other Parties to the extent practicable under the circumstances and subject to any practicable arrangements to protect confidentiality, to the extent required under the rules of any stock exchange or by applicable laws or governmental regulations or judicial or regulatory process or generally accepted accounting principles applicable to any Party or in connection with any judicial process regarding any legal action, suit or proceeding arising out of or relating to this Agreement; and

 

iv)                                  disclosure by NPIP or Napo of Confidential Information concerning NPIP or Napo or the terms of this Agreement that is reasonably necessary in the ordinary course of business or otherwise in connection with or pursuant to transactions or proposed transactions of NPIP or Napo, including but not limited to a listing on AIM or the London Stock Exchange.

 

v)                                     disclosure by NPIP or Napo of Confidential Information to existing investors of Napo.

 

13)                              FURTHER ASSURANCES

 

a)                                     Each Party shall, at any time and from time to time upon the written request of any other Party:

 

i)                                         promptly and duly execute and deliver all such further instruments and documents, and do or procure to be done all such acts or things, as such other Party may reasonably deem necessary or desirable in obtaining the full benefits of this Agreement and of the rights and ownership herein granted;

 

ii)                                      do or procure to be done each and every act or thing which such other Party may from time to time reasonably require to be done for the purpose of enforcing such other Party’s rights under this Agreement.

 

14)                              INDEMNITY

 

a)                                     Napo undertakes to indemnify and keep indemnified for a period of two (2) years from the date of this Agreement (the “Indemnified Period”) the Investor and its directors (the “Investor Parties”) against any loss, liability, claims, costs and expenses directly suffered by the Investor Parties as a result of, or in connection with or arising from a breach by Napo of the NPIP warranties and/or Napo Warranties and/or any terms of the

 

19

 

Transaction Agreements not to exceed $500,000 in the aggregate (collectively, the “Losses”).  Such indemnity shall extend to include all costs, charges and expenses which Investor may pay or incur in disputing or defending any claim or action or other proceedings where authorized in accordance with the provisions of this Clause in respect of which indemnity may be sought under this Clause.

 

b)                                     Notwithstanding the foregoing, without in any way limiting the obligation of Napo to indemnify the Investor Parties pursuant to the above Clause, Napo shall not be required to indemnify the Investor Parties for breach of any NPIP Warranties and/or Napo Warranties and/or any terms of the Transaction Agreements (A) unless written notice thereof has been given by the Investor Parties during the Indemnified Period and (B) unless and until the aggregate dollar amount of all Losses resulting or arising from any and all such breaches exceeds an aggregate of $50,000, at which point Napo shall indemnify the Investor Parties for the aggregate amount of all such Losses incurred, not to exceed $500,000 in the aggregate for all such Losses.

 

c)                                      The foregoing indemnities of Napo shall not apply with respect to any breach by Napo of NPIP Warranties and/or Napo Warranties and/or any terms of the Transaction Agreements that results in a claim by a third party, unless the Investor Parties shall, with reasonable promptness, provide Napo with copies of any claims or other documents received and shall otherwise make available to Napo all relevant information material to the defense of any claim against the Investor Parties which shall serve as the basis for a claim by the Investor Parties pursuant to the terms hereof.  Notwithstanding the foregoing, the Investor Parties’ failure to give prompt notice or to provide copies of documents or to furnish relevant information shall not constitute a defense (in part or in whole) to any claim by the Investor Parties against Napo, except and only to the extent that such failure by the Investor Parties shall result in material prejudice to Napo.  Napo shall have thirty (30) days (or such shorter period as may be necessitated by the exigencies of such claim) within which to elect to defend such claim at its own expense and with counsel of its own choosing (who shall be reasonably acceptable to the Investor Parties), provided that the Investor Parties shall have the right at all times to fully participate in the defense thereof at their own expense.  Napo may not settle or compromise any such claim without the prior written consent of the Investor Parties, which consent shall not unreasonably be withheld unless as part of the settlement Napo obtains an unconditional release of the Investor Parties.  If Napo shall, within such thirty (30) days (or shorter) period, fail to defend such claim with counsel reasonably acceptable to the Investor Parties, the Investor Parties shall have the right, but not the obligation, to undertake the defense of such claim.  The Investor Parties may not settle or compromise any such claim without the prior written consent of Napo, which consent shall not be unreasonably withheld unless as part of the settlement the Investor Parties obtain an unconditional release of Napo.

 

d)                                     Any claim of indemnity made by the Investor Parties under this Clause must be made in good faith in a writing executed by an officer of the Investor (the “Notice of Claim”) delivered to Napo within the Indemnified Period, and, if raised by such date, such claim shall survive until final resolution thereof.  Any such Notice of Claim will set forth with reasonable specificity the nature of the claim for indemnity and, if then determinable, the

 

20

 

approximate amount of the claimed Losses, and shall include copies of any formal demand or complaint.

 

e)                                      For the avoidance of doubt, Napo shall be liable in accordance with the terms of this indemnity in respect of the business, operation and activities of Napo and NPIP to the extent such business, operation and activities of Napo and NPIP are the subject matter of a breach of the NPIP Warranties and/or Napo Warranties.

 

f)                                       Napo shall ensure that NPIP enjoys the benefit of suitable director and officers insurance policy to cover its employees and directors and such director and officers insurance policy will not be terminated without the consent of the Investor.

 

15)          NOTICES

 

a)                                     Each notice, demand or other communication given or made under this Agreement shall be in writing and delivered to the relevant Party at its address or fax number set out below (or such other address or fax number as the addressee has by three (3) Business Days’ prior written notice specified to the relevant Party):

 

	
To NPIP:
    	
 
    	
Napo Pharmaceuticals India Private Limited
    Napo Pharmaceuticals, Inc.
 250 E. Grand Avenue, Suite 70
 South San Francisco, CA 94080
    
	
 
    	
 
    	
 
    
	
To Investor:
    	
 
    	
IL&FS Investment Managers Ltd.
    IL&FS Financial Centre
 C-22, G Block,
 Bandra Kuria Complex
 Bandra (East), Mumbai 400 051
 India
 Attention: Mr. Sunil Diwakar
    
	
 
    	
 
    	
 
    
	
To Napo:
    	
 
    	
Napo Pharmaceuticals, Inc.
    250 E. Grand Avenue., Suite 70
 South San Francisco, California 94080
 USA
 Attention: Chief Executive Officer
    
	
 
    	
 
    	
 
    
	
Copy:
    	
 
    	
Donald C. Reinke
    Reed Smith LLP
 2 Embarcadero Center, 20th Floor
 San Francisco, CA 94111
 Fax: 415.391.8269
    

 

Any notice, demand or other communication so addressed to the relevant party shall (a) where sent by registered post or private courier shall be deemed to have been delivered

 

21

 

when actually delivered to the relevant address and receipt is confirmed by the government or private carrier; and (b) where sent via facsimile, shall be deemed to have been delivered upon receipt of a transmission report confirming dispatch.

 

16)          GOVERNING LAW AND DISPUTE SETTLEMENT

 

a)                                     Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of India, without effect to its principles of conflict of laws.

 

b)                                     Arbitration.  In the case of any dispute or claim arising out of or in connection with or relating to this Agreement, or the breach, termination or invalidity hereof, the Parties shall attempt to first resolve such dispute or claim through discussions between senior executives of each Party.  If the dispute is not resolved through such discussions within ten (10) Business Days after one Party has served a written notice on the other Party requesting the commencement of consultation, such dispute shall be referred to the highest ranking executive of each Party for resolution.  If the dispute is still not resolved through discussions between the highest ranking executives of the Parties within a further seven (7) Business Days, then the dispute or claim shall be finally settled by arbitration under the United Nations Commission on International Trade Law Arbitration Rules (the “UNCITRAL Rules”) as are in force at the time of any such arbitration and as may be amended by the rest of this Clause 16(b).  For the purpose of such arbitration, there shall be three arbitrators who shall be appointed by the relevant Parties in accordance with the UNCITRAL Rules (the “Arbitration Board”).  The Investor shall appoint one (1) arbitrator and the CEO of Napo shall appoint one arbitrator who shall represent the Napo Group.  The two arbitrators so appointed shall appoint the third arbitrator as may be mutually agreed amongst them.  All arbitration proceedings shall be conducted in the English language and the place of arbitration shall be in Mumbai.  The Parties shall be entitled to seek injunctive reliefs from the courts of India having jurisdiction.  The arbitrators shall decide any such dispute or claim strictly in accordance with the governing law specified in Clause 16(a).  Judgement upon any arbitral award rendered hereunder may be entered in any court having jurisdiction, or application may be made to such court for a judicial acceptance of the award and an order of enforcement, as the case may be.

 

c)                                      Good Faith.  Each Party shall co-operate in good faith to expedite (to the maximum extent practicable) the conduct of any arbitral proceedings commenced under this Agreement.

 

d)                                     Costs and Expenses.  The costs and expenses of the arbitration (other than attorneys fees and expenses), including, without limitation, the fees of the arbitration and the Arbitration Board, shall be determined by the Arbitration Board.  The Arbitration Board would have the power to award interest on any sum awarded pursuant to the arbitration proceedings and such sum would carry interest, if awarded, until the actual payment of such amounts.

 

e)                                      Final and Binding.  Subject to applicable Law, any award made by the Arbitration Board shall be final and binding on each of the Parties that were parties to the dispute.

 

22

 

17)          TERM

 

a)                                     This Agreement shall come into effect on the Effective Date and shall continue until the Investor ceases to hold any OCRPSs and all the Shares including Converted Shares at which time, this Agreement and the obligations and rights of each Party shall terminate, provided, however, that Clauses 11, 12, 13, 14, 15, 16 and 18 shall survive any such termination.

 

18)          MISCELLANEOUS

 

a)                                     Amendment: This Agreement may not be amended, modified or supplemented except by a written instrument executed by Napo, NPIP, and Investors.

 

b)                                     Waiver: No waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by the party waiving such provision.  No failure or delay by a Party in exercising any right, power or remedy under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of the same preclude any further exercise thereof or the exercise of any other right, power or remedy.  Without limiting the foregoing, no waiver by a Party of any breach by another Party of any provision hereof shall be deemed to be a waiver of any subsequent breach of that or any other provision hereof.

 

c)                                      Assignment: Neither this Agreement nor any of the rights or obligations hereunder shall be assignable, except with the mutual written consent of Napo, NPIP and the Investor.  Provided that upon a transfer by the Investor of its OCRPSs and Shares (including Converted Shares) to a Person in accordance with this Agreement, it shall have the right to assign all its rights and obligations under this Agreement to such Person except the board rights or affirmative rights pursuant to Clause 9 unless the transfer is to an Affiliate.

 

d)                                     Entire Agreement: This Agreement, any Investor Subscription Agreements and the schedules and annexures attached hereto constitute the entire agreement and understanding between the Parties with respect to the subject matters herein, and supersede and replace any prior agreements and understandings, whether oral or written between and among them with respect to such matters.

 

e)                                      Severability: Each and every obligation under this Agreement shall be treated as a separate obligation and shall be severally enforceable as such and in the event of any obligation or obligations being or becoming unenforceable in whole or in part.  To the extent that any provision or provisions of this Agreement are unenforceable they shall be deemed to be deleted from this Agreement, and any such deletion shall not affect the enforceability of the remainder of this Agreement.

 

f)                                       Counterparts and Facsimile Signatures: This Agreement may be executed in one or more counterparts which, signed and taken together, shall constitute one document.  A facsimile signature on this Agreement, if legible and complete, will be regarded as an original signature.

 

23

 

g)                                      Consent to Specific Performance.  The Parties declare that it is impossible to measure in money the damages that would be suffered by a Party by reason of the failure by any other Party to perform any of the obligations hereunder.  Therefore, if any Party shall institute any action or proceeding to seek specific performance or enforcement of the provisions hereof, any Party against whom such action or proceeding is brought hereby waives any claim or defence therein and the other Party has an adequate remedy at law

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

24

 

IN WITNESS WHEREOF, this Agreement has been executed on the day and year first above written.

 

 

	
/s/   Lisa A. Conte
    	
 
    
	
FOR AND ON BEHALF OF NAPO PHARMACEUTICALS INDIAPRIVATE LIMITED
    	
 
    
	
By:
    	
Lisa   A. Conte
    	
 
    
	
Title:
    	
Director
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/   Lisa A. Conte
    	
 
    
	
FOR AND ON BEHALF OF NAPO PHARMACEUTICALS INC.
    	
 
    
	
By:
    	
Lisa   A. Conte
    	
 
    
	
Title:
    	
Director
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/   [Name of Signatory]
    	
 
    
	
FOR AND ON BEHALF OF L&FS INVESTMENT MANAGERS LIMITED
    	
 
    
	
By:
    	
 
    
	
Title:
    	
 
    

 

 

ANNEXURE 1

 

DEED OF ADHERENCE

FORM OF DEED OF ADHERENCE

 

THIS DEED (“DEED”) IS MADE ON              DAY OF       , 200[ ] BETWEEN:

 

A.                                    IL&FS TRUST COMPANY LIMITED, a company incorporated under the Companies Act, 1956 having its Registered Office at The IL&FS Financial Centre, Plot No C-22, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051, as the trustee (“Trustee”) of the IL&FS Private Equity Trust, a trust established under the Indian Trusts Act, 1882, which is a Venture Capital Fund registered with the Securities and Exchange of India, investing through its venture capital scheme Leverage India Fund, which shall, unless repugnant to the subject or context, mean and include the Trustee for the time being and from time to time of the said trust, its successors and assigns acting through its investment manager IL&FS INVESTMENT MANAGERS LIMITED, a company incorporated in India under the Companies Act, 1956 and having its registered office at the IL&FS Financial Centre, C-22, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India (hereinafter referred to as “Investor”, which expression shall, unless repugnant to the context or meaning thereof, mean and include its successors and assigns);

 

B.                                    NPIP PRIVATE LIMITED, a company organised and existing under the Companies Act, 1956, whose registered office is at Office No. 1Z, 91, Nagdevi X Lane, 2nd Floor Mumbai 400080, India, (hereinafter referred to as “NPIP” which expression shall, unless repugnant to the context or meaning thereof, be deemed to include its successors and permitted assigns);

 

C.                                    NAPO PHARMACEUTICALS, INC., a company organised and existing under laws of the State of Delaware, USA, whose registered office is at 250 E. Grand Avenue, Suite 70, South San Francisco, California 94080, USA (hereinafter referred to as “Napo” which expression shall, unless repugnant to the context or meaning thereof, be deemed to include its successors and permitted assigns); and

 

D.            [               ] (the New Shareholder);

 

WHEREAS:

 

(A)                               The Investor, NPIP and Napo are parties to an Investment Rights Agreement dated [ ] (the Agreement).

 

(B)                               The New Shareholder proposes to purchase for [ ] OCRPSs/ Shares of Rs.  [ ] each in the capital of NPIP from the Investor, for a purchase price of [ ].

 

(C)                               This deed is made by the New Shareholder in compliance with Clause 5(a) of the Agreement.

 

 

THIS DEED WITNESSES AS FOLLOWS:

 

(1)                                 Capital terms used but not defined in this Deed shall have the respective meanings given to such terms in the Agreement.

 

(2)                                 The New Shareholder confirms that it has been supplied with a copy of the Agreement.

 

(3)                                 The New Shareholder hereby purchases [ ] OCRPSs/ Shares of Rs.  [ ] each in the capital of NPIP from the Investor at a purchase price of Rs.  [ ] per OCRPS/ Share and agrees to hold the shares subject to Agreement and the memorandum and articles of association of NPIP.

 

(4)                                 The New Shareholder undertakes to NPIP and Napo to be bound by the Agreement in all respects as if the New Shareholder was a party to the Agreement and named in it as the Investor and to observe and perform all the provisions and obligations of the Agreement applicable to or binding on the Investor under the Agreement insofar as they fall to be observed or performed on or after the date of this deed.  Provided that the New Shareholder shall not under any circumstances have the board rights or affirmative voting and veto rights of the Investor pursuant to Clause 9 of the Agreement.

 

(5)                                 Napo and NPIP undertake to the New Shareholder to observe and perform all the provisions and obligations of the Agreement applicable to or binding on them under the Agreement and acknowledge that the New Shareholder shall be entitled to the rights and benefits of the Agreement as if the New Shareholder were named in the Agreement in place of Investor as a shareholder with effect from the date of this deed.  Provided that the New Shareholder shall not under any circumstances have the board rights or affirmative voting and veto rights of the Investor pursuant to Clause 9 of the Agreement.

 

(6)                                 This deed is made for the benefit of (a) the parties to the Agreement and (b) every other person who after the date of the Agreement (and whether before or after the execution of this deed) assumes any rights or obligations under the Agreement or adheres to it.

 

(7)                                 The New Shareholder hereby represents and warrants, as of the date hereof, to Napo and NPIP Team as follows:

 

(i)                                     The New Shareholder has the legal capacity and the full power, authority to enter into this Deed and to perform the obligations set out in this Deed and the Agreement and has duly executed and delivered this Deed;

 

(ii)                                  Neither the execution of this Deed nor the performance by the New Shareholder of any of its obligations hereunder or under the Agreement will conflict with or result in a breach of any provisions of any law, regulation, judgment, order, authorization, agreement or obligation or document binding on or applicable to the New Shareholder.

 

(iii)                               No event is outstanding which constitutes (or with the giving of notice, lapse of time or making of any determination or satisfaction of other conditions, is likely to constitute) a default under any other document or obligation assumed or otherwise binding on the New Shareholder to an extent which has or is reasonably

 

27

 

likely to have a material adverse effect on the performance of the obligations by the New Shareholder under this Deed or the Agreement.

 

(iv)                              The New Shareholder has not granted or agreed to grant in favour of any person any interest in or any option or other rights in respect of any of the OCRPSs/ Shares of NPIP to be held by it.

 

(8)                                 The address and facsimile number of the New Shareholder for the purposes of Clause 15 of the Agreement is as follows:                [  ]

 

(9)                                 This deed may be executed in any number of counterparts, all of which taken together shall constitute one and the same deed and any party may enter into this deed by executing a counterpart.

 

(10)                          This deed is governed by and shall be construed in accordance with Indian law.  The terms and conditions of the Agreement in relation to the provisions regarding arbitration shall be deemed to have been incorporated in this Deed.

 

IN WITNESS OF WHICH THIS DEED HAS BEEN EXECUTED AND HAS BEEN DELIVERED ON []

 

28

 

	
 
    	
 
    
	
FOR AND ON BEHALF OF [NEW SHAREHOLDER]
    	
 
    
	
By:
    	
 
    
	
Title:
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
FOR AND ON BEHALF OF NAPO PHARMACEUTICALS INDIA PRIVATE LIMITED
    	
 
    
	
By:
    	
Lisa   A. Conte
    	
 
    
	
Title:
    	
Director
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
FOR AND ON BEHALF OF NAPO PHARMACEUTICALS INC.
    	
 
    
	
By:
    	
Lisa   A. Conte
    	
 
    
	
Title:
    	
Director
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
FOR AND ON BEHALF OF L&FS INVESTMENT MANAGERS LIMITED
    	
 
    
	
By:
    	
 
    	
 
    
	
Title:Exhibit 10.72

 

*** TEXT OMITTED AND SUBMITTED PURSUANT TO CONFIDENTIAL TREATMENT REQUEST

 

MARKETING AND DISTRIBUTION AGREEMENT

 

This MARKETING AND DISTRIBUTION AGREEMENT (this “Agreement”) is made as of April 14, 2016 (the “Effective Date”), by and among Napo Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 301 Main Street # 30G, San Francisco, California 94105 (“Napo”), and BexR Logistix, LLC, a Texas limited liability company (“BexR”) with its principal place of business at 10999 Interstate Highway 10 West, Suite 1000, San Antonio, TX 78230-1355.  (Napo and BexR are also sometimes referred to herein as the “parties” or individually as a “party”).

 

RECITALS

 

A.                                    Napo is in the business of developing and commercializing pharmaceuticals, including the drug Fulyzaq® (Crofelemer).

 

B.                                    BexR provides logistical support and product consignment services to a broad range of industries, including pharmaceutical companies.

 

C.                                    Napo wishes to engage BexR, and BexR wishes to be so engaged, to provide certain telemarketing, consignment and distribution services pursuant to the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants and agreements herein contained, Napo and BexR hereby agree as follows:

 

1.                                      Appointment

 

1.1                               Distributor.  Subject to the terms and conditions of this Agreement, Napo appoints BexR as its distributor with the right to telemarked and sell (as described in Section 4.9 of this agreement), and the exclusive right to distribute the prescription drug Fulyzaq® (Crofelemer) (the “Product”) during the Term of this Agreement in the United States and its Territories (the “U.S.”), and BexR accepts such appointment.

 

2.                                      Napo’s Agreements

 

2.1                               Product.  Napo agrees to make, or to cause to be made, the Product available to BexR for sale to customers in a manner consistent with the written forecasts of Product sales prepared and provided by BexR and delivered to and accepted in writing by Napo.  Napo shall be responsible for planning and coordinating the relabeling of existing Product inventory, including modification of bottle labels and package inserts.  Should Napo wish to engage Mission in coordination of repacking Product, there will be a pass-thru cost plus coordination fee to be determined.  Napo shall be responsible for the creation of a sample unit for the Product.  Napo shall be the owner of the Product paying BexR for the consignment services including storage, shipping and distribution services and telemarketing services it will also provide.

 

2.2                               Marketing and Marketing Strategy.  Napo shall develop a marketing plan (“Marketing Plan”) for the Product, including a budget for advertising and promotion expenses, based on net revenue benchmarks.                  Napo will prepare, at Napo’s sole expense, all

 

 

documentation, advertising and sales promotion materials, instructions, and manuals relating to the Product (collectively, “Product Materials”).  Napo agrees to spend a minimum of $[***] (which shall include any fees paid to SmartPharma for its marketing services and the Advance from BexR which will be detailed in Exhibit A “the Marketing Plan” upon approval by Napo) for Product Materials and commercialization of the Product during the first twelve (12) months of the Agreement.  In connection with the marketing strategy and unless agreed otherwise by BexR, Napo shall purchase and analyze market data (IMS or Symphony), including national and physician-level data.  Napo shall develop web site content for promotion of the Product.  In coordination with BexR, Napo shall develop a prescriber target list.

 

2.3                               Intellectual Property.  Napo shall maintain all patents, trademarks, URLs and other intellectual property related to the Product, as determined in Napo’s sole business judgment.

 

2.4                               Reimbursement and Managed Care Strategy.  In cooperation with and based on input from BexR, Napo shall develop a managed care strategy for sales to customers, including pricing discounts and rebates.  Napo shall analyze current co-payment assistance programs and develop and negotiate new or additional co-payment assistance programs as needed based upon the Marketing Plan.

 

2.5                               Regulatory Approvals.  Napo shall own the NDA for the Product and shall be responsible for obtaining and maintaining all required regulatory approvals, and for all communications with federal, state and local authorities in the U.S. (“Governmental Entities”).  Napo shall be responsible for obtaining all approvals from Governmental Entities for labeling and relabeling of the Product.

 

2.6                               Training.  Napo shall develop speaker development and training for key opinion leaders, including development of training content, training materials and event planning.  Napo shall review and revise sales training materials and develop new training materials as needed specific to the Product.  Napo shall conduct Product specific sales training for BexR telemarketing representatives.

 

3.                                      Term.  The Term of this Agreement shall be four (4) years commencing as of the Effective Date (“Initial Term”).  The Agreement will renew automatically for successive one (1) year terms (“Subsequent Terms”) unless written notice of termination is provided by either party to the other party not less than 90 days prior to the expiration of the then current Initial or Subsequent Term (the Initial Term, plus any Subsequent Terms, collectively, the “Term”).

 

*** Confidential Treatment Requested

 

2

 

4.                                      BexR’s Agreements

 

4.1                               NDA and NDC.  BexR shall assist Napo with transfer of the Product New Drug Application (“NDA”) from Valeant Pharmaceuticals International, Inc., as successor to Salix Pharmaceuticals, Inc. (“Valeant”) and shall coordinate with Napo to obtain a new National Drug Code (“NDC”) for the Product, including assistance with interactions with the FDA regarding the foregoing, and thereafter, assist Napo with the maintenance of the NDA in the U.S. as defined in Exhibit B.

 

4.2                               Sunshine Act and Prescription Drug Promotion Reporting Compliance.  Upon request, BexR shall assist Napo with the Compilation of data under Section 6002 of the Patient Protection and Affordable Care Act “Sunshine Act” (a.k.a. “Open Payments”) expense reporting.  Such data shall include all information reasonably necessary to permit Napo to complete any transparency or “Sunshine” reporting requirements which may be applicable under state or federal laws, including assistance with the completion of Form 2253 submissions to the Office of Prescription Drug Promotion Reporting.

 

4.3                               Pharmacovigilance.  BexR shall assist Napo in the development and implementation of policies, standard operating procedures and applicable infrastructure for compliance with drug safety and consumer protection.  BexR shall provide call center staffing and assistance with professional and consumer inquiries.  BexR shall prepare the appropriate documentation in compliance of annual reports and of reported adverse events, and will provide these to Napo for FDA submission.  Further, BexR shall provide support for all product inquiries received by healthcare professionals and consumers regarding Product, and assist Napo in the development of all medical communications as set forth in a separate pharmacovigilance agreement which the Parties agree to finalize within thirty (30) days of Closing.

 

4.4                               Warehousing and Distribution of Finished Product.  BexR shall store and distribute the finished Product, BexR shall provide inventory management to facilitate finished Product supply, including communication with Napo and other contract development, supply chain, and finished product manufacturers.  BexR shall arrange for and coordinate all trade services, including contract management with wholesalers, group purchasing organizations and others, handling sales transactions, and management of wholesale incentives, rebates and returns.  BexR shall provide retail trade support, as needed, and any other post-finished Product supply chain requirements.

 

4.5                               Managed Care Contracts and Rebates.  BexR shall assist Napo in transitioning managed care contracts, including the structure and management of rebates.  Upon request, BexR shall assist Napo in the negotiation of new managed care contracts on terms and conditions, including discount and rebate terms, provided by Napo.  BexR shall assist Napo with preparation, negotiation and implementation of managed care contracts with Governmental Entities, including contracts under the federal and state Medicare and Medicaid programs and VA pricing agreements and the like, and with managing communications with such Governmental Entities.

 

 

4.6                               Promotional Review.  BexR shall provide regulatory, medical, and legal recommendations of all promotional materials prepared by Napo with respect to the Product.  The final decision on all labeling and promotional materials shall be made by Napo.

 

4.7                               Delegation.  BexR shall use subcontractors as needed to complete these and other tasks in the Agreement and shall maintain a written contract with third parties for these services, including a Nondisclosure Agreement with each subcontractor.

 

4.8                               Non-Personal Promotion and Marketing Support.  As agreed upon, BexR shall provide the following non-personal promotion services:

 

(a)                                 Selling and tele-detailing to an agreed upon target list (the “Non-Personal Promotion Target List”);

 

(b)                                 Distribution of samples to the Non-Personal Promotion Target List;

 

(c)                                  Implementation of co-pay assistance program for non-personal prescribers.

 

5.                                      Fees

 

5.1                               Advance.  Upon execution of this Agreement, BexR shall place [***] Dollars ($[***]) (the “Advance”) in a designated account (the “Account”) to cover necessary and reasonable expenses of Napo relating to commercialization of the Product.

 

5.2                               Expenditures from the Account.  Napo may draw funds from the Account to pay reasonable commercialization expenses, including but not limited to, costs related to the following:

 

(a)                                 Transfer of inventory from Valeant to Napo’s or BexR’s warehouse;

 

(b)                                 Relabeling of inventory, including printing new package inserts and bottle labels, purchase of bottles, and repackaging;

 

(c)                                  Packaging of portions of Product inventory as samples;

 

(d)                                 Purchase of market data, including prescriber-level data for the HIV antiretroviral market and for Product prescribers;

 

(e)                                  Reasonable honoraria and out of pocket expenses for market research and development of training for key opinion leaders related to the Product, to be conducted by SmartPharma, LLC or another vendor mutually agreed upon by the parties;

 

(f)                                   Out of pocket costs for design and printing of promotional materials;

 

(g)                                 Out of pocket costs for development of copay assistance program;

 

*** Confidential Treatment Requested

 

 

(h)                                 Out of pocket costs for revision of sales training materials; and

 

(i)                                    Additional expenses as agreed upon by Napo and BexR.

 

Napo shall provide monthly reports to BexR within ten (10) days of the end of each month, detailing the expenses paid from the Account during the prior month.

 

5.3                               Repayment of Advance.  Napo shall repay the entire Advance to BexR within the first twenty-four (24) months when Napo has access to the Advance in the Account (the “Payment Period”).  Napo shall make quarterly payments to repay the Advance commencing on the first day of the third quarter after the first sale of the Product under a Napo NDC code.  The quarterly payments shall be equal to $[***] per dollar of Net Sales for the first quarter payment, $[***] per dollar of Net Sales for the second quarter payment and $[***] per dollar of Net Sales for the remaining quarterly payments.  In the event that Napo has not repaid the Advance to BexR by the end of the Payment Period, Napo shall pay the entire outstanding balance to BexR within ten (10) days of the end of the Payment Period.

 

5.4                               Consignment Revenue Share.  As consideration for the provision of services under this Agreement, Napo shall pay BexR a share of Napo’s Net Sales equal to:  [***] percent ([***]%) of Net Sales for the first twelve (12) months following the first sale of the Product under a Napo NDC code; [***] percent ([***]%) of Net Sales for the second twelve (12) month period; and [***] percent ([***]%) for each twelve (12) month period thereafter until the Agreement is terminated.  Beginning in the third twelve (12) month period, Napo shall pay BexR the [***] ([***]) percent of Net Sales up to and including a cap of $[***]for any twelve (12) month period.  BexR will pay Napo its share of Net Sales forty-five (45) days after month-end for the first sixty (60) days of the Agreement.  Thereafter, BexR will pay Napo its share of Net Sales sixty (60) days after month-end.  BexR may reduce any amount currently owed to BexR prior to distributing the amounts due to Napo.  For purposes of this Agreement, Net Sales means the gross amount invoiced by BexR for the sale of the Product, less deductions for (a) trade discounts, returns, allowances, fees, reimbursements, rebates, and chargebacks to wholesalers and distributors, buying groups, pharmacy benefit managers, insurance carriers, and distributors; (b) freight, postage, shipping, and insurance expenses; (c) customs and excise duties; (d) rebates and payment to Governmental Entities, under government programs, such as Medicare and Medicaid; (e) sales and other taxes and duties; (f) any other similar or customary deductions consistent with GAAP; and (g) any invoiced amounts not collected by BexR.

 

6.                                      Compliance with Laws.  Each party shall, and shall cause its customers to comply with all foreign, federal, state and local rules, regulations, ordinances and laws applicable to their respective businesses and the use, operation, handling, storage, shipment and distribution of the Product, including without limitation, the U.S. Food, Drug and Cosmetics Act, the federal and state anti-kickback laws, Section 34013 of the Public Health Services Act, and the Sunshine Act.  BexR does not assume any obligation for Napo’s compliance with law.  BexR and BexR’s customers are solely responsible for the use and operation of the Product in accordance with all applicable laws and regulations, and medical and treatment guidelines, and for ensuring that each operator of the Product is adequately trained and qualified to use and operate each Product safely and properly in a clinical setting and to perform medical procedures in accordance with such laws, regulations and guidelines.  Each party represents and warrants that it is aware of and

 

*** Confidential Treatment Requested

 

5

 

currently in compliance with, and covenants that it will at all times comply with, all anti-bribery and anti-corruption laws applicable to doing business in the areas in which the parties do business, including, but not limited to, the U.S. Foreign Corrupt Practice Act (the “FCPA”) and, if applicable, anti-bribery legislation enacted in accordance with the Organization for Economic Co-operation and Development Convention on Combating Bribery of Foreign Public Officials in International Business Transactions.  Each party agrees to comply with all other regulations or industry codes of conduct applicable to its business.

 

7.                                      Mutual Governance.  Mission shall assign an Account Manager, who shall serve as a key point of contact to Napo for all issues arising and related to the Business.

 

8.                                      Proceedings.  If either party receives notice of an actual or threatened inspection, investigation, field action, warning, inquiry, import or export ban, product seizure, enforcement proceeding or similar action by a Governmental Entity with respect to the Product or either party’s activities in connection with the Product, the party receiving such notice shall notify the other in writing within two (2) business days after its receipt of notice of the action and will promptly deliver to the other party copies of any relevant documents received from the government authority.  Napo and BexR shall cooperate in response to the action, including but not limited to providing information and documentation as requested by the Government Entity.  If the action primarily concerns one party’s activities, that party shall have primary responsibility to respond to the Governmental Entity and to pay all expenses related thereto.  In either case, upon request of the responding party, the other party shall reasonably cooperate and provide consulting advice and assistance with the response.

 

9.                                      Indemnification.  Each party shall indemnify the other against all claims, damages, losses, and expenses, including reasonable attorneys’ fees (collectively, “Losses”), arising out of (i) such party’s performance or failure to perform in accordance with the terms and conditions of this Agreement, whether caused by such party’s action or inaction, negligence or the negligence of its employees or agents; and (ii) such party’s failure to comply with the laws, statutes, rules, regulations or orders of any governmental authority having jurisdiction over such party or its business.  However, the parties agree that under no circumstances shall BexR be liable for any losses alleged due to lower than forecasted sales amounts, ineffective marketing campaigns, or alleged lost sales of the Product.

 

10.                               Insurance.  Each party will maintain commercial general liability insurance, including blanket contractual liability insurance covering the obligations (within the scope of insurance) of that party under this Agreement through the term of this Agreement and for a period of three (3) years thereafter, which insurance will afford limits of not less than (i) $5,000,000 for each occurrence for personal injury or property damage liability; and (ii) $5,000,000 in the aggregate with respect to product and completed operations liability.  The above limit requirements may be satisfied with the combination of an Umbrella or Excess Liability policy.  Napo’s commercial general liability and product and completed operations liability policies shall be endorsed to (i) name Provider as an additional insured; (ii) waive all rights of subrogation against Provider and; (iii) act as primary/non-contributory coverage over any other valid and collectable coverage available to Provider.  Each party will provide the other with a certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the effective date, the expiration date and the limits of liability.  The insurance certificate will further

 

 

provide for a minimum of thirty (30) days’ written notice (except ten (10) days for non-payment of premium) to the insured of a cancellation of the insurance.  If a party is unable to maintain the insurance policies required under this Agreement through no fault on the part of such party, then such party will forthwith notify the other party in writing and the parties will in good faith negotiate appropriate amendments to the insurance provision of this Agreement in order to provide adequate assurances.

 

11.                               Adverse Event Reporting.  Each party shall notify the other immediately of (a) any adverse comments or complaints by prescribers, users or Governmental Entities regarding the Product, including comments regarding the Product’s quality, stability, contamination, potency, condition, packaging, or any other attributes or defects, and (b) any adverse events that may be attributable to use of the Product, whether or not such party can confirm that the event is actually associated with the Product, and whether or not such party can confirm that the event was due to improper dosing or other negligence on the part of any party.  In the event of an actual or alleged defect of the Product, neither party nor its representatives or agents shall make any statement as to the cause of the event until the parties have agreed upon a proposed communication strategy.

 

12.                               Product Recall.  Napo has the exclusive right to determine if a recall of Product is required and shall bare all expense related to all recalls.

 

13.                               Further Obligations.  During the Term, each party shall:

 

(a)                                 not without the other party’s prior written consent make any promises or guarantees about the Product beyond those contained in the Product Materials agreed upon by the parties;

 

(b)                                 employ a sufficient number of suitably qualified personnel to ensure the proper fulfillment of its obligations under this Agreement;

 

(c)                                  keep full and proper books of account and records clearly showing all inquiries, quotations, transactions and proceedings relating to the Product;

 

(d)                                 not make any modifications to the Product, Product labeling or Product instructions for use or packaging except as contemplated by this Agreement;

 

(e)                                  maintain and store the Product in accordance with all applicable laws and regulations, in a manner that will prevent any compromise of or change in the Product and at a facility that is operated in compliance with all applicable laws and regulations;

 

(f)                                   present the Product fairly to potential prescribers and users and not disparage the Product or the other party in any way;

 

(g)                                 not authorize, promote or permit any unapproved use of the Product;

 

(h)                                 not offer, pay or arrange for any rebate, kickback, bribe or other remuneration to potential prescribers or users in exchange for agreement to prescribe, purchase or use the Product;

 

7

 

(i)                                    not market or distribute the Product for any off-label use;

 

(j)                                    ensure that all sales and marketing personnel involved in promoting and marketing the Product are adequately trained with respect to the Product;

 

(k)                                 ensure that no personnel employed or under contract with BexR are or have been subject to debarment or exclusion under any federal or state program; and

 

(l)                                    make available, and use its best efforts to provide, to any prescribers and other users of the Product all training and continuing education necessary to ensure the proper usage of the Product.

 

14.                               Proprietary Information

 

14.1                        Confidentiality.  Each party shall treat as confidential and proprietary all data and information disclosed by the other party that is proprietary to, or a trade secret of, such disclosing party (collectively, “Proprietary Information”) and shall not disclose such Proprietary Information to any person not in the disclosing party’s employment or to any person in the disclosing party’s employment not having a specific need to know such Proprietary Information in connection with his or her employment, and shall use such Proprietary Information only in connection with its proper performance of this Agreement.  Each party agrees to be liable for any use or disclosure of Proprietary Information in violation of this Agreement by any of its employees, consultants and professional advisors who have access to or are otherwise provided such Proprietary Information.  Proprietary Information shall include, but is not limited to, data and information labeled as such by a party, hut shall not include any data or information that is in the public domain through no fault or breach of this Agreement by a party.  Neither party shall cause its employees or agents to, reverse engineer, decompile, disassemble or copy any Proprietary Information, including, without limitation, any data or information relating to the Product.

 

14.2                        Injunctive Relief.  Each party acknowledges that there is no adequate remedy at law for any breach of this Section 14.  Accordingly, each party agrees that the other party shall be entitled to seek injunctive relief, without necessity of posting a bond, to restrain any actual or threatened breach of this Section 14.

 

15.                               Termination

 

15.1                        Termination.  This Agreement may be terminated prior to the end of any Term as follows:

 

(a)                                 Breach.  Either party may terminate this Agreement immediately upon written notice to the other in the event the other party breaches this Agreement;

 

(b)                                 With Notice.  Either party may terminate this Agreement without cause upon 90 days prior written notice to the other party.

 

(c)                                  Bankruptcy/Insolvency.  Either party may terminate this Agreement immediately upon written notice to the other party in the event that proceedings in bankruptcy or

 

8

 

insolvency are instituted by or against the other party, or a receiver is appointed for the other party, or if any substantial part of the assets of the other party is the object of attachment, sequestration or other type of comparable proceeding, and such proceeding is not vacated or terminated within thirty (30) days after its commencement or institution.

 

15.2                        Payment of Advance on Termination.  In the event that either party elects to terminate this Agreement prior to the end of the Term pursuant to this Section 15, Napo shall immediately pay to BexR the entire outstanding balance of the Advance owed to BexR pursuant to Section 5.3 of this Agreement.

 

15.3                        Option.  Upon termination of this Agreement pursuant to this Section 15, BexR shall have the first right of negotiation to license the Product if Napo decides to out-license any remaining commercial rights of the Product

 

15.4                        Termination Fee.  If Napo terminates this Agreement during the first two years, a Termination Fee shall be paid by Napo to Mission:

 

(a)                                 The Termination Fee for termination during the first year of the Agreement shall be equal to twenty percent (20%) of Napo’s Net Sales for the last thirty (30) days prior to termination, multiplied by the number of months remaining in the first year of the Agreement.  A partial month shall be pro-rated.  The Termination Fee for termination during year two of the Agreement shall be equal to fifteen percent (15%) of Napo’s Net Sales for the last thirty (30) days prior to termination, multiplied by six (6).

 

16.                               General Provisions

 

16.1                        Notices.  All notices and other communications in connection with this Agreement shall be in writing and shall be sent to the respective parties at the addresses set forth in the Preamble hereof, or to such other addresses as may be designated by the respective parties in writing from time to time in accordance with this Section 18.1, by personal delivery, or by registered or certified air mail, postage prepaid, or by express courier service, service fee prepaid, or by facsimile with a hard copy to follow via air mail or express courier service, service fee prepaid.  All notices shall be deemed received (i) if given by hand, immediately, (ii) if given by air mail, ten (10) business days after posting, (iii) if given by express courier service, the next business day in the jurisdiction of the recipient or (iv) if given by facsimile, upon delivery of the facsimile transmittal, provided that a confirmation copy is sent by regular mail.

 

16.2                        Independent Contractor.  It is expressly agreed and understood that BexR is, and at all times shall be, an independent contractor and not an employee or agent of Napo.  Napo shall have no right to direct the time, manner and method by which BexR shall accomplish its work nor shall Napo have the right to control the manner in which any services to be rendered by BexR are to be performed.  Nothing in this Agreement shall be construed to characterize the relationship between the parties as that of employer/employee, principal/agent, franchisor/franchisee, partnership or co-venture.  All expenses and disbursements that either party may incur in connection with this Agreement shall be borne wholly and completely by such party.  Neither party shall have any right or authority to commit or legally bind the other

 

9

 

party in any way.  All financial obligations associated with each party’s business are the sole responsibility of such party.

 

16.3                        Entire Agreement; Amendments.  This Agreement sets forth the full understanding and entire agreement between the parties concerning its subject matter, and supersedes all prior oral and written understandings and agreements relating thereto.  No terms, conditions, understandings or agreements purporting to modify or amend this Agreement shall be effective unless made in writing and signed by both parties.  Neither party has relied upon any representation or statement of the other except as stated in this Agreement.  All amendments of this Agreement, notices and communications between the parties, and all materials supplied under this Agreement by either party to the other, shall be in the English language.

 

16.4                        Severability.  In the event that any one or more of the provisions contained herein, or the application thereof in any circumstances, is held invalid, illegal or unenforceable in any respect for any reason in any jurisdiction, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions hereof shall not be in any way impaired or affected, it being intended that each of party’s rights and privileges shall be enforceable to the fullest extent permitted by law.

 

16.5                        Governing Law; Consent to Jurisdiction.  This Agreement shall be governed by and interpreted in accordance with the laws of the State of Texas.  The parties hereby submit to the jurisdiction and venue of any state or federal court located within the State of Texas for resolution of any and all claims, causes of action and disputes arising out of, related to or concerning this Agreement.

 

16.6                        Assignments; Subcontracting.  Neither party may assign, transfer or otherwise dispose of this Agreement or any interest therein, or subcontract any of its obligations hereunder, in whole or in part to any individual, firm or corporation without the prior written consent of the other party.  Notwithstanding the foregoing, BexR shall entitled to appoint subcontractors or representatives, contract with affiliates and assign this Agreement to its affiliates, provided that BexR shall promptly inform Napo of the appointment of any such subcontractor or representative or an assignment.  BexR shall cause any subcontractor, representative or assignee so appointed to comply with all requirements of this Agreement.

 

16.7                        Waiver of Compliance.  Any failure by any party hereto to enforce at any time any term or condition under this Agreement shall not be considered a waiver of that party’s right thereafter to enforce each and every term and condition of this Agreement.

 

16.8                        Force Majeure.  Neither party shall be liable for failure or delay in performance of any obligation under this Agreement, other than payment of any amount due and payable, if such failure or delay is caused by circumstances beyond the control of the party concerned, including, without limitation, failures resulting from fires, explosion, flood, riot, accidents, labor stoppages, war, inability to secure materials or labor, government acts or regulations or acts of God.

 

16.9                        No Third Party Beneficiaries.  Nothing in this Agreement is intended to confer any rights or remedies under or by reason of this Agreement on any persons other than the

 

10

 

parties and their respective successors and permitted assigns.  Nothing in this Agreement is intended to relieve or discharge the obligations or liability of any third persons to any of the parties.  No provision of this Agreement shall give any third persons any right of subrogation or action over or against any of the parties.

 

16.10                 Expenses.  Each of the parties hereto shall pay the fees and expenses of its respective counsel, accountants and other advisors and shall pay all other expenses incurred by it in connection with the negotiation, preparation and execution of this Agreement and the consummation of the transactions contemplated by this Agreement.

 

16.11                 Headings.  The headings of the sections and paragraphs of this Agreement have been inserted for convenience of reference only and shall not be deemed to be part of this Agreement.

 

16.12                 Counterparts.  This Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which when so executed and delivered shall be an original, but all of which together shall constitute one and the same instrument, and it shall not be necessary in making proof of this Agreement to produce or account for more than one such counterpart.

 

[signature page follows]

 

11

 

IN WITNESS WHEREOF, the parties have executed this Agreement as an instrument under seal on the day and year first above written by their representatives duly authorizes for such purposes.

 

	
 
    	
NAPO PHARMACEUTICALS, INC.
    
	
 
    	
a   Delaware corporation
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/Lisa   A Conte
    
	
 
    	
Name:   Lisa A. Conte
    
	
 
    	
Title:   Chief Executive Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
BEXR LOGISTIX, LLC,   a Texas limited liability company
    
	
 
    	
 
    
	
 
    	
By:
    	
 /s/Dan Harmon
    
	
 
    	
Name:   Dan Harmon
    
	
 
    	
Title:   General Manager, BexR Logistix, LLC
    

 

 

FIRST AMENDMENT TO MARKETING AND DISTRIBUTION AGREEMENT

 

THIS FIRST AMENDMENT TO THE MARKETING AND DISTRIBUTION AGREEMENT (this “Amendment”) is made and entered into as of July 19, 2016, and made effective on July 19, 2016 by and between BexR Logistix, LLC (“BexR”), with its principal business office located at 10999 IH-10 West, Suite 1000, San Antonio, Texas 78230, and Napo Pharmaceuticals, Inc. (“Napo”), with its principal business office located at 201 Mission Street, Ste. 2375, San Francisco, California 94105.

 

W I T N E S S E T H:

 

A.                                    Napo and Mission originally entered into that certain Marketing and Distribution Agreement dated April 14, 2016 (the “Agreement”).

 

B.                                    Napo and Mission agree to the change of the trademarked Product name in the Agreement from Fulyzaq® to MytesiTM

 

C.                                    Napo and Mission desire to amend the Agreement as more fully set forth herein.

 

NOW, THEREFORE, in consideration of the mutual promises and covenants and agreements more fully set forth herein, and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

Except as provided herein, all terms and conditions of the Agreement and any prior amendments shall remain in full force and effect without change through the Term of the Agreement.  The amended Recitals and Sections of the Agreement set forth below shall replace in its entirety the same numbered Recitals and Sections in the Agreement and is incorporated into the Agreement as binding Recitals and Sections of the Agreement on the Parties.

 

D.                                    The Recitals A, B, and C in the Agreement shall be replaced with the following recitals:

 

RECITALS

 

A.                                    Napo is in the business of developing and commercializing pharmaceuticals, including the drug MytesiTM (Crofelemer).

 

B.                                    BexR provides logistical support and product consignment services to a broad range of industries, including pharmaceutical companies.

 

C.                                    Napo wishes to engage BexR, and BexR wishes to be so engaged, to provide certain telemarketing, consignment and distribution services pursuant to the terms and conditions set forth in this Agreement

 

E.                                     Section 1(a), “Appointment,” shall be replaced with the following Section 1(a) to reflect the agreed change of the trademarked name of the Product:

 

 

1.                                      Appointment

 

a.                                      Distributor.  Subject to the terms and conditions of this Agreement, Napo appoints BexR as its distributor with the right to telemarket and sell (as described in Section 4.9 of this agreement), and the exclusive right to distribute the prescription drug MytesiTM (Crofelemer) (the “Product”) during the Term of this Agreement in the United States and its Territories (the “U.S.”), and BexR accepts such appointment.

 

IN WITNESS WHEREOF, the parties have executed this First Amendment to Marketing and Distribution Agreement as of the date set forth above.

 

	
 
    	
NAPO PHARMACEUTICALS, INC.
    
	
 
    	
a   Delaware corporation
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/Lisa   A Conte
    
	
 
    	
Name:   Lisa A. Conte
    
	
 
    	
Title:   CEO
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
BEXR LOGISTIX, LLC,   a Texas limited liability company
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/Thomas   J. Dooley
    
	
 
    	
Name:   Thomas J. Dooley
    
	
 
    	
Title:   Treasurer
    

 

14

 

SECOND AMENDMENT TO MARKETING AND DISTRIBUTION AGREEMENT

 

THIS SECOND AMENDMENT TO THE MARKETING AND DISTRIBUTION AGREEMENT (this “Amendment”) is made and entered into as of February 27, 2017, by and between BexR Logistix, LLC (“BexR”), with its principal business office located at 10999 IH-10 West, Suite 1000, San Antonio, Texas 78230, and Napo Pharmaceuticals, Inc. (“Napo”), with its principal business office located at 201 Mission Street, Ste. 2375, San Francisco, California 94105.

 

W I T N E S S E T H:

 

Napo and BexR entered into a Marketing and Distribution Agreement (the “Agreement”) dated as April 14, 2016.  Napo and BexR entered into a First Amendment to the Marketing and Distribution Agreement dated July 19, 2016.

 

NOW, THEREFORE, in consideration of the mutual promises and covenants and agreements more fully set forth herein, and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

Except as provided herein, all terms and conditions of the Agreement and any prior amendments shall remain in full force and effect without change through the Term of the Agreement.  The amended Section of the Agreement set forth below shall replace in its entirety the same numbered Section in the Agreement and is incorporated into the Agreement as a binding Section of the Agreement on the Parties.

 

Section 5.3, “Advance,” shall be replaced with the following Section 5.3:

 

5.3                               Repayment of Advance

 

Amended loan amount shall be $267,500.00 payable to Mission Pharmacal Company to start July 2017 on a payment schedule set forth below:

 

	
Deferral
    	
 
    	
Dec
    	
 
    	
Jan
    	
 
    	
Feb
    	
 
    	
March
    	
 
    	
Apr
    	
 
    	
May
    	
 
    	
Jun
    	
 
    	
Jul
    	
 
    	
Aug
    	
 
    	
Sep
    	
 
    	
Oct
    	
 
    	
Nov
    	
 
    	
Dec
    	
 
    	
Jan
    	
 
    	
Total
    	
 
    
	
New Deferral
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
32,100
    	
 
    	
$
    	
32,100
    	
 
    	
$
    	
34,775
    	
 
    	
$
    	
40,125
    	
 
    	
$
    	
40,125
    	
 
    	
$
    	
42,800
    	
 
    	
$
    	
45,475
    	
 
    	
$
    	
267,500
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
12.00
    	
%
    	
12.00
    	
%
    	
13.00
    	
%
    	
15.00
    	
%
    	
15.00
    	
%
    	
16.00
    	
%
    	
17.00
    	
%
    	
100.00
    	
%
    
																																															

 

In the event that Napo has not repaid the Advance to BexR by the end of the Payment Period, Napo shall pay the entire outstanding balance to BexR within ten (10) days of the end of the Payment Period.

 

IN WITNESS WHEREOF, the parties have executed this Second Amendment to Marketing and Distribution Agreement as of the date set forth above.

 

[Signature Page follows]

 

 

	
 
    	
NAPO PHARMACEUTICALS, INC.
    
	
 
    	
a   Delaware corporation
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/Lisa   A Conte
    
	
 
    	
Name:   Lisa A. Conte
    
	
 
    	
Title:   Chief Executive Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
BEXR LOGISTIX, LLC,   a Texas limited liability company
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/Thomas   J. Dooley
    
	
 
    	
Name:   Thomas J. Dooley
    
	
 
    	
Title:   Treasurer
    

 

16

 

THIRD AMENDMENT TO MARKETING AND DISTRIBUTION AGREEMENT

 

THIS THIRD AMENDMENT TO THE MARKETING AND DISTRIBUTION AGREEMENT (this “Amendment”) is made and entered into as of March 31, 2017, by and between BexR Logistix, LLC (“BexR”), with its principal business office located at 10999 IH-10 West, Suite 1000, San Antonio, Texas 78230, and Napo Pharmaceuticals, Inc. (“Napo”), with its principal business office located at 201 Mission Street, Ste. 2375, San Francisco, California 94105.

 

W I T N E S S E T H:

 

Napo and BexR entered into a Marketing and Distribution Agreement (the “Agreement”) dated as April 14, 2016.  Napo and BexR entered into a First Amendment to the Marketing and Distribution Agreement dated July 19, 2016.  Napo and BexR entered into a Second Amendment to the Marketing and Distribution Agreement dated February 27, 2017.

 

NOW, THEREFORE, in consideration of the mutual promises and covenants and agreements more fully set forth herein, and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

Except as provided herein, all terms and conditions of the Agreement and any prior amendments shall remain in full force and effect without change through the Term of the Agreement.  The amended Section of the Agreement set forth below shall replace in its entirety the same numbered Section in the Agreement and is incorporated into the Agreement as a binding Section of the Agreement on the Parties.

 

Section 5.3, “Advance,” shall be replaced with the following Section 5.3:

 

5.3                               Repayment of Advance

 

Amended loan amount shall be $267,500.00 payable to BexR to start July 2017 on a payment schedule set forth below:

 

	
Deferral
    	
 
    	
Dec
    	
 
    	
Jan
    	
 
    	
Feb
    	
 
    	
March
    	
 
    	
Apr
    	
 
    	
May
    	
 
    	
Jun
    	
 
    	
Jul
    	
 
    	
Aug
    	
 
    	
Sep
    	
 
    	
Oct
    	
 
    	
Nov
    	
 
    	
Dec
    	
 
    	
Jan
    	
 
    	
Total
    	
 
    
	
New Deferral
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
—
    	
 
    	
$
    	
32,100
    	
 
    	
$
    	
32,100
    	
 
    	
$
    	
34,775
    	
 
    	
$
    	
40,125
    	
 
    	
$
    	
40,125
    	
 
    	
$
    	
42,800
    	
 
    	
$
    	
45,475
    	
 
    	
$
    	
267,500
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
12.00
    	
%
    	
12.00
    	
%
    	
13.00
    	
%
    	
15.00
    	
%
    	
15.00
    	
%
    	
16.00
    	
%
    	
17.00
    	
%
    	
100.00
    	
%
    
																																															

 

In the event that Napo has not repaid the Advance to BexR by the end of the Payment Period, Napo shall pay the entire outstanding balance to BexR within ten (10) days of the end of the Payment Period.

 

IN WITNESS WHEREOF, the parties have executed this Second Amendment to Marketing and Distribution Agreement as of the date set forth above.

 

[Signature Page follows]

 

 

	
 
    	
NAPO PHARMACEUTICALS, INC.
    
	
 
    	
a   Delaware corporation
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/Lisa   A Conte
    
	
 
    	
Name:   Lisa A. Conte
    
	
 
    	
Title:   Chief Executive Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
BEXR LOGISTIX, LLC,   a Texas limited liability company
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/Thomas   J. Dooley
    
	
 
    	
Name:   Thomas J. Dooley
    
	
 
    	
Title:   Treasurer
    

 

18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]